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ABSTRACT
Evaluation of Blood Vessel Mimic Scaffold Biocompatibility
Nicole Marie Abraham
The Tissue Engineering Research Lab at California Polytechnic State University, San Luis
Obispo focuses on creating tissue-engineered blood vessel mimics (BVMs) for use in preclinical
testing of vascular devices. These BVMs are composed of electrospun scaffolds made of an
assortment of polymers that are seeded with different cell types. This integration of polymers with
cells leads to the need for biocompatibility testing of the polymer scaffolds. Many of the lab’s
newest scaffolds have not been fully characterized for biologic interactions. Therefore, the first aim
of this thesis developed methods for in vitro cytotoxicity testing of polymers used in the fabrication
of BVMs. This included cytotoxicity testing using direct contact and elution-based methods, along
with fluorescent staining to visualize the scaffold effects on cells.
The second aim of this thesis implemented the newly developed cytotoxicity protocols to
evaluate the biocompatibility of existing polymers, ePTFE and PLGA, used in the tissue
engineering lab. The results demonstrated that ePTFE and PLGA were noncytotoxic to cells. The
third aim of this thesis evaluated the biocompatibility of novel polymers used to fabricate BVMs:
PLGA with salt, PLLA, and PCL. Elution-based methods concluded that PLGA with salt, PLLA,
and PCL were noncytotoxic to cells; however, the direct contact method illustrated PLGA with salt
and PCL were mildly cytotoxic at 24 and 48 hours. Potential causes of this variability include the
addition of salt to PLGA, dissolving PCL in dichloromethane, inadequate sample sizing, and the
inherent differences between the test methods. Overall, this thesis developed and implemented
methods to evaluate the biocompatibility of polymer scaffolds used in the BVM model, and found
that ePTFE, PLGA, and PLLA scaffold materials were biocompatible and could be implemented
in future BVM setups without concerns. Meanwhile, PLGA with salt and PCL’s toxicity was mild
enough to urge future cytotoxicity testing on PLGA with salt and PCL before further use in the lab.
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CHAPTER 1. INTRODUCTION
1.1 Overview
The Tissue Engineering Research Lab at California Polytechnic State University, San Luis
Obispo is run by Dr. Kristen Cardinal, who focuses the lab’s innovative work on creating tissueengineered models for use in preclinical testing. With cardiovascular disease being the leading
cause of death and disability worldwide [1], the field continuously works to meet the critical need
for reliable and improved treatments. Hence, the creation of tissue-engineered blood vessel mimics
(BVMs) intended to serve as preclinical models for evaluating intravascular stents and other
vascular devices. BVMs are composed of electrospun polymer scaffolds seeded with human
vascular cell types and cultivated in a flow-based bioreactor system to mimic the vasculature’s
physiological environment in vitro. The scaffolds can be composed of an assortment of polymers,
all of which will contact different cell types, leading to the need for biocompatible scaffold
materials. Many of the lab’s newest scaffold materials have not been fully characterized for
biocompatibility. Therefore, the overall goal of this master’s thesis was to evaluate biocompatibility
of existing and novel BVM scaffolds materials. This Introduction will serve to provide background
and foundation in the areas relevant to this work—including basic blood vessel anatomy, pathology,
and treatments for cardiovascular disease, the components and fabrication of blood vessel mimics
for device testing, a deeper look at BVM scaffolds, the electrospinning process, and
biocompatibility testing.
1.2 Native Blood Vessel Anatomy
To establish a comparison between the blood vessel mimics and the anatomy of the native
vasculature, researchers must first understand the native blood vessel anatomy. A blood vessel is
made up of three layers: the tunica intimae, the tunica media, and the tunica adventitia (Fig. 1). The
adventitia, the outermost layer of the vessel, provides structural support and shape to the vessel.
The tunica media, the middle layer of the vessel, regulates the vessel's internal diameter and is
1

composed of elastic and muscular tissue. The tunica intima, the innermost layer of the vessel,
provides housing for the flow of blood. The vessel's size and location determine the amount of
muscle and collagen fibrils present within each vessel layer [2].

Figure 1. Blood Vessel Anatomy. The vessel wall comprises three layers: tunica adventitia,
tunica media, and tunica intima [3].

The tunica media, or vascular wall, comprises a broad layer of connective tissue and
numerous layers of smooth muscle cells (SMCs). In contrast, the tunica adventitia consists of
loosely organized adventitial fibroblasts. The endothelium lines the lumen, the hollow passageway
through which blood flows, and consists of a dense layer of endothelial cells (ECs) [2]. An
abundance of endothelial cells is always present, no matter the blood vessels' size or function (Fig.
2). Each layer and cell type provides a unique function. ECs and SMCs are critical cell types due
to their role in vessel strength preservation and mechanical property management. More
specifically, SMCs have secretory capabilities that help maintain elasticity and radial compliance
of the vessel. In contrast, the EC layer provides selective permeability, a thrombo-resistant barrier,
facilitation of laminar blood flow through the lumen, vessel tone, platelet activation, cell adhesion,
and much more [2].

2

Figure 2. Cross-section of a Small Artery. The endothelial cells are the fundamental component
of the blood vessel, although seemingly scarce [4].

1.3 Cardiovascular Disease Pathology and Treatments
As stated in Section 1.1, cardiovascular disease is the leading cause of death and disability
worldwide. An estimated 17.9 million people die of related cardiac disorders each year, including
heart and vascular diseases [5]. These diseases can be caused by several factors, the most common
being atherosclerosis, plaque buildup, irregular heartbeats, congenital heart defects, and
cardiomyopathies [6]. Atherosclerosis (Fig. 3) is an inflammatory disease that involves the
accumulation of lipids within the arterial wall. It leads to the hardening and narrowing of coronary
arteries, which eventually restricts blood flow to the heart [7]. In the United States, 1.4 million
patients per year are subjected to operations requiring arterial prostheses, and about 100,000
patients require vascular bypass of arteries to treat atherosclerotic disease [8]. These alarming
statistics justify the need for improved treatments of cardiovascular disease.

3

Figure 3. Stages of Atherosclerosis. Normal artery compared to a mild atherosclerotic artery and
a severe atherosclerotic artery [9].

Current techniques used to treat cardiovascular disease include lifestyle changes,
medications, bypass surgery, and intravascular stents. These treatments have shown success, but
also come with limitations [10]. The most commonly used grafts for bypass surgeries are
autologous arteries and veins, or those obtained from the same individual. Because of either
previous surgery, burns, trauma, disease, etc., these options are unavailable to 10% of
cardiovascular disease patients [11]. Along with this, purely synthetic polymer constructs have led
to failures due to the early formation of thrombosis [2]. These limitations have led to the
development of tissue-engineered blood vessels [12].
Intravascular devices are also a common option for treating cardiovascular disease.
Mechanical devices such as bare-metal stents, drug-eluting stents [13], bioresorbable vascular
scaffolds [14], amongst others are types of intravascular devices that increase the efficacy of
angioplasty while decreasing the possibility of restenosis, or reduction in vessel lumen diameter
after angioplasty. Limitations of these intravascular devices include, but are not limited to, access
site bleeding, stent under-expansion, stent thrombosis, and incomplete revascularization [14].
4

Therefore, novel treatments for cardiovascular disease continue to be researched and developed to
overcome these challenges. With the development of novel treatments comes the need for new
methods and models to help establish safety and efficacy.
1.4 Blood Vessel Mimics for Device Testing
Extensive preclinical testing must be done to characterize medical device safety before
being introduced into animal models or human clinical testing. The traditional progression of
medical device testing before being approved for market involves extensive in vitro/benchtop
testing, followed by in vivo/animal testing, and lastly clinical testing in humans (Fig. 4). Preclinical
studies are an essential first step in demonstrating the safety of a medical device and, if done
correctly, can provide considerable data and insight into the future and effectiveness of a device or
material being tested. Using tissue-engineered models as a part of preclinical testing can provide a
valuable understanding of devices or materials before introducing them into animals and humans.
One such example of a tissue-engineered model is a blood vessel mimic, shown in the Figure 4
below, which provides a scalable, biologic vascular model that serves as an intermediate testing
environment.

Figure 4. Typical Progression of Device Testing. New devices typically undergo initial in vitro
testing on materials or components, followed by testing in animal models, and eventually clinical
trials. Blood vessel mimics have been developed as an intermediate testing environment to
provide information about a device in a more complex environment before being used in animal
models [15].
5

1.5 Blood Vessel Mimic Components and Fabrication
Blood vessel mimics provide a valuable, vascular testing model and it is important to
understand their components. The fundamental components of an in vitro tissue-engineered blood
vessel mimic (BVM) include three traditional building blocks: cells, scaffolds, and bioreactors. For
BVMs to best mimic the native vasculature, they must provide, at the least, a simple blood vessel
structure. Therefore, the BVM models are comprised of vascular cell types, an electrospun polymer
scaffold, and a perfusion system bioreactor (Fig. 5).

Figure 5. The bioreactor system: peristaltic pump connected to a media reservoir and chamber
containing the vessel of interest [16].

The components of the BVMs used in Kristen Cardinal’s lab consist of a polymer scaffold
with a cellular lining made of human endothelial cells (ECs) and sometimes smooth muscle cells
(SMCs), because these are the cell types found within the native blood vessel. Human Umbilical
Vein Endothelial Cells (HUVECs) are most commonly used in the BVM lab after being cultured
in medium, passed, and maintained at 37 °C and 5% CO2 for expansion.
While cells are being cultured for use in the BVMs, scaffolds are simultaneously prepared.
In general, the role of a scaffold is to mimic the extracellular matrix (ECM) of a native blood vessel.
6

A scaffold is the biomaterial that contributes to the structure and mechanical properties of the BVM,
as well as to the formation of new tissue in vivo. Therefore, the scaffold material should be
functionally non-thrombogenic, non-immunogenic, compatible with high blood flow rates, and
have similar viscoelasticity to native vessels [2]. Along with this, the scaffolds used in tissue
engineering applications must be easily sterilizable and able to maintain their sterility. Scaffolds
can be composed of several different types of biomaterials or polymers depending on the
application and desired use. A closer look at BVM scaffolds will be provided in Sec 1.6.
Once the desired cells are properly expanded and scaffolds are prepared, a bioreactor
system becomes necessary. A bioreactor is defined as a device capable of creating the proper
environment for a biologic product [17]. The bioreactor’s primary role is to provide housing and a
controlled environment for a scaffold and cell construct. This involves controlling temperature, pH,
and gas, transporting nutrients, and simulating blood flow. There are several types of bioreactors
found in the tissue engineering field: including spinner flasks, rotating wall bioreactors, and flowbased bioreactors. In the BVM lab, a flow-based bioreactor is assembled and utilized for blood
vessel cultivation. The bioreactor is connected to a peristaltic pump and media reservoir that allow
for continuous transluminal or transmural flow of media throughout the system and scaffold.
With all the components selected and prepared, BVMs are fabricated by combining the
polymeric scaffold with previously cultured cells and cultivating the construct in the assembled
bioreactor (Fig. 6). First, the fabricated scaffold is cut to the appropriate size and sutured onto
fittings for later conditioning. Once the scaffold fits the desired measurements, it undergoes the
process of conditioning within the bioreactor before adding and cultivating cells. Conditioning
involves the scaffold being flushed and coated with “conditioning media” that contains proteins
necessary for cell adhesion and growth. The polymeric scaffolds are then sodded, or injected and
covered, with ECs and/or SMCs and cultivated to create a complete BVM. The resulting scaffold
and cell construct is incubated in the bioreactor system for a specified timepoint while connected
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to a peristaltic pump and media reservoir. Once the timepoint is completed, the cultivated construct
is then harvested from the system and chemically fixed to preserve its current state for imaging and
analysis.

Figure 6. The sequential steps in preparing the cells, scaffold, and bioreactor for the
creation of a tissue-engineered blood vessel [15].

1.6 A Deeper Look at BVM Scaffolds
A key component of a BVM is the scaffold, which provides the vessel's structural and
mechanical integrity. To fabricate BVMs, researchers must choose an appropriate biomaterial for
the scaffold. These biomaterials are determined based on specific criteria, for example, whether
they are natural or synthetic and degradable or non-degradable. In Dr. Cardinal’s Tissue
Engineering Lab, the standard polymers used have been expanded Polytetrafluoroethylene (ePTFE)
and Poly(lactic-co-glycolic acid) (PLGA). Newer polymers and polymer combinations that the lab
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has more recently explored include PLGA with salt, Poly-L-lactic Acid (PLLA), and
Polycaprolactone (PCL).
Polytetrafluoroethylene (PTFE), also known as Teflon, is a synthetic polymer made via
tetrafluoroethylene polymerization (Fig. 7). This polymer can be expanded to create ePTFE, which
has a microporous structure that enhances the polymer by providing a high strength-to-weight ratio,
considerable biocompatibility, high thermal resistance, and high porosity [18]. This polymer is
well-established with notable biocompatibility [19]. ePTFE has been used in many medical devices,
including vascular grafts, stents, cardiovascular and soft tissue patches, facial implants, surgical
sutures, and endovascular prostheses [20]. While this polymer seems to hold many desirable
characteristics for tissue engineering, it is not degradable, and it is not something that can be
fabricated or customized internally at Cal Poly. Along with this, the expanded polymer’s
hydrophobic surface provides an unfavorable non-adhesion property, making it challenging to coat
its surface with any enhancing technologies (i.e. coatings that increase cell adhesion and/or growth)
[21]. Therefore, although ePTFE was used for many years as the lab’s BVM scaffold, it has been
recently replaced by several other degradable and more tailorable polymers.

Figure 7. Polytetrafluoroethylene. Made from the monomer tetrafluoroethylene by free radical
vinyl polymerization [22].

The most common, recently used scaffold in the BVM lab is Poly(lactic-co-glycolic acid)
(PLGA). PLGA consists of two monomers, lactic acid and glycolic acid, and has the molecular
structure displayed in Figure 8 below. PLGA is used in many biomedical applications including as
9

scaffolds, hydrogels, and injectable microspheres in bone tissue engineering [23], as nanoparticles
in drug delivery systems [24], and in vascular tissue engineered devices [25]. This is a widely used
polymer due to its low level of toxicity, biocompatibility, tailorable biodegradation rate, prevalence
in devices approved for clinical use in humans, and its potential to be surface-modified to enhance
cell interaction, adhesion, and growth [23]. One disadvantage of PLGA is its suboptimal
mechanical properties when used in load-bearing applications. This is why PLGA is commonly
combined with other materials to enhance its mechanical properties [23]. Additionally, PLGA has
shown undesirable stiffness within the BVM lab, especially when compared to ePTFE [26].
Although there are limitations of using PLGA, it was ultimately selected as a polymer for BVM
fabrication for the reasons stated previously, along with the fact that it dissolves in many common
solvents, including tetrahydrofuran, acetone, ethyl acetate, and chlorinated solvents [27]. This
solubility factor makes it beneficial for the lab’s BVM, as electrospinning requires the polymer to
be dissolved in various solvents [28]. Another benefit of PLGA is its porous matrix, which provides
a cell-favorable structure that promotes cell adhesion, migration, and growth. Overall, PLGA was
deemed an appropriate polymer for electrospinning BVM scaffolds due to its ability to be
electrospun into fibrous, porous constructs, its ability to provide critical cellular responses under
shear stress, its ability to be ethyl alcohol (EtOH) gas sterilized, and its low cost [27].

Figure 8. Poly(lactic-co-glycolic acid). The molecular structure of PLGA with x and y indicating
the number of times each unit repeats [28].
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While PLGA possesses desirable polymer properties and characteristics for scaffold
fabrication, the addition of sodium chloride (NaCl) or other salts into the polymer solution may be
beneficial. The addition of salt results in a more viscous electrospinning solution, which creates
scaffolds with uniformly distributed pores from the interior region to the surface of the scaffold.
While PLGA plus salt scaffolds can maintain their structural integrity, the salt addition also seems
to weaken the mechanical properties of scaffolds [29]. More specifically, experiments have shown
how scaffolds constructed of PLGA without salt result in constructs with denser morphology, larger
pores, and substantial leaching, while scaffolds constructed of PLGA with salt result in constructs
with smaller pores and thus less leaching [30]. Pore size and interconnection between pores are
essential components in scaffold fabrication when thinking about eventual cell sodding, adhesion,
and growth; therefore, the addition of salt to PLGA was desirable for the BVM lab. This will be
further introduced in Section 1.7.1.
An even more recent polymer that has been implemented is PLLA. PLLA is the L-isomer
of polylactic acid (PLA) (Fig. 9), a thermoplastic polymer common in biodegradable medical
device applications. PLLA is a known biodegradable, biocompatible, and biologically inert
polymer [31]. PLLA’s notable degradability occurs from the natural degradation of the polymer in
situ through the mechanism of hydrolysis. The disadvantages of PLLA include low toughness (due
to brittleness), slow degradation rate (due to crystalline structure and molecular weight),
hydrophobicity (due to a static water contact angle of about 80°), and the lack of reactive side chain
groups (due to chemical inertness). These disadvantages can lead to plastic deformation at highstress levels, an extensive lifetime of devices in vivo, low cell affinity, inflammatory response upon
direct contact to biological fluids, and challenging surface functionalization and bulk modification
[32]. Although PLLA has several undesirable properties, the polymer’s material properties, such
as composition or molecular weight, can be tailored to potentially better suit the BVM. This ability
to be tailored makes it an ideal candidate in applications such as bone fixation screws, bioresorbable
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suture threads, and stent coatings [32]. When PLLA is fabricated, the polymer can provide highly
porous and fibrous scaffolds. The resulting structure from electrospinning PLLA closely mimics
the natural extracellular matrix and leads to improved cell adhesion and growth throughout the
scaffold [33]. Although PLLA comes with limitations, the polymer has many desirable
characteristics that make it valuable to the BVM lab.

Figure 9. Poly-L-lactic Acid (PLLA). The molecular structure of PLLA with n indicating the
number of times each unit repeats [34].

Another more recent polymer that has been introduced to the BVM lab is PCL. PCL is a
synthetic polyester (Fig. 10) that degrades by hydrolysis under physiological conditions and is used
in many medical applications, such as in implantable biomaterials and in capsules for controlled
release and targeted drug delivery [35]. This synthetic polyester is biodegradable, biocompatible,
nontoxic, has desirable mechanical properties (i.e., high strength), and is readily available. Like
PLLA, PCL has a slow degradation rate and high permeability [35]. Disadvantages of PCL in tissue
engineering include its hydrophobic surface, which can decrease cell retention, along with the fact
that solvents used in fabrication of this polymer can be toxic to cells [36]. Although there are several
disadvantages to PCL, it is known to be a material with exceptional electrospinning properties. The
polymer's nanofibrous structures when spun provide a large surface area, small diameter of pores,
and a high porosity that make it ideal for the fabrication of an electrospun polymer [37]. Therefore,
it is a favorable polymer for use in BVM scaffold fabrication.
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Figure 10. Polycaprolactone (PCL). The molecular structure of PCL with n indicating the
number of times each unit repeats [35].

Overall, a variety of polymer scaffolds have been explored and implemented for BVMs. A
summary of these polymers is provided in Table 1. As mentioned previously, fabrication plays a
key role in polymer properties. As described in Section 1.5, Cal Poly’s Tissue Engineering Lab
uses an electrospinning process to fabricate structured microfiber or nanofiber scaffolds. This
process contributes to the polymer structure and properties, and requires the use of a solvent, which
impacts biocompatibility. Specifics about the electrospinning process will be covered in the next
section.
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Table 1. Summary table of polymers that have been used as BVM scaffolds.
Polymers

Example Uses in
Research Lab

Example Uses in
the Medical Field

Advantages

Disadvantages

ePTFE

Tissue-engineered
vascular grafts as in
vitro BVMs [38],
Assessment of
BVMs with optical
coherence
tomography [39],
Development of an
in-vitro tissue
engineered BVM
[40]

Vascular grafts,
stents,
cardiovascular
and soft tissue
patches, facial
implants, surgical
sutures, and
endovascular
prostheses [20]

Microporous
structure, high
strength-to-weight
ratio,
biocompatibility,
high thermal
resistance, high
porosity [18]

Nondegradable,
cannot be
fabricated or
customized
internally at
Cal Poly,
hydrophobic
surface [21]

PLGA

Preparation and
characterization of
electrospun PLGA
scaffolds [27],
Electrospinning
polymer scaffolds
for tissue
engineered BVMs
[41], Custom tissue
engineered
aneurysm models
[42], Tissueengineered
aneurysm
models[43]

Porous or fibrous
scaffolds,
hydrogels, and
injectable
microspheres in
bone tissue
engineering [23],
nanoparticles in
drug delivery
systems [24],
vascular tissue
engineering
devices [25]

Minimal toxicity,
biocompatibility,
tailored
biodegradation rate,
ability to modify
surface properties
to provide better
cell interaction [23],
ability to provide
critical cellular
responses under
pulsatile flow,
ability to be EtO
gas sterilized in
house, low cost [27]

Less than ideal
mechanical
properties
when used in
load-bearing
applications
[23],
undesirable
stiffness [26]

PLLA

Evaluation of new
polymers for
electrospinning
tissue engineered
BVMs [44]

Bone fixation
screws,
bioresorbable
suture threads,
stent coatings [32]

Biodegradable,
biocompatible, and
biologically inert
[31]

Low toughness,
slow
degradation
rate,
hydrophobicity,
lack of reactive
side-chain
groups [32]

PCL

Evaluation of new
polymers for
electrospinning
tissue engineered
BVMs [44]

Implantable
biomaterials,
providing a
capsule for
controlled release,
targeted drug
delivery [35]

Biodegradable,
biocompatible,
nontoxic, strength,
ease of availability,
slow degradation
rate, high
permeability [35]

Hydrophobic
surface, low
cell retention,
solvents that
can be toxic to
cells [36]
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1.7 Electrospinning
Electrospinning is a widely used scaffold fabrication technique in the tissue engineering
field. Researchers use electrospinning for many different applications, including tissue engineering
and drug delivery [45]. Except for ePTFE, which has been obtained from commercial vendors, all
other BVM scaffolds in Dr. Cardinal’s Tissue Engineering Lab have been created in-house via
electrospinning. The electrospinning process utilizes a DC voltage to spin fine, small diameter
fibers from a chosen polymer solution onto an area of the researcher’s choice to create the desired
scaffold shape. An electrospinning apparatus, shown generically below in Figure 11, consists of
three components: a high voltage power supply, a spinneret, and a grounded collector (in the lab’s
case, a rotating mandrel or a flat plate). Once the polymer of choice is completely dissolved within
a specific solvent and placed into a syringe, an electric charge is applied to the polymer solution
surface. The charged solution is then forced out of the syringe tip and rapidly whipped around
within the gap between the syringe tip and the collector, thus evaporating the solvent and leaving
fibers of the polymer on the collecting mandrel [46]. The resulting scaffold is then removed from
the collecting mandrel and placed into a desiccator for moisture removal.

Figure 11. Electrospinning set up. Schematic diagram of the horizontal setup of an
electrospinning apparatus [45].
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The key variables and parameters in the electrospinning process are the polymer type,
solvent type, collector/mandrel size, gap distance between the spinneret and the collector, syringe
pump flow rate, and applied voltages. An advantage of the electrospinning process is the ability to
create different fiber morphology and fiber diameters from the adjustment of these parameters. In
addition, the process is a very simple, versatile, and cost-effective way to create non-woven fibers
with high surface area to volume ratio, controllable porosity, and adequate mechanical properties.
Along with this, electrospinning creates scaffolds with fiber diameters that mimic the native tissue
environment, which promote cell-matrix and cell-cell interactions, and thus encourage cell growth,
as seen in Figure 12 below [46], [47].

Figure 12. Comparison of Electrospun Scaffolds to that of a Native Airway ECM. Scanning
electron microscope (SEM) images of a decellularized basement membrane (A), a cross-section
of a decellularized airway bronchiole, (C), and a histological section of an airway smooth muscle
bundle stained with hematoxylin and eosin (H&E), scale bar 40 um (E) compared with nanofiber
(B) biphasic (D) and aligned (F) PET electrospun scaffolds [47].
16

1.7.1 Electrospinning of More Tailored Scaffolds
Along with using the electrospinning process to fabricate the BVM lab’s standard tissueengineered blood vessels, the lab has also used it to create more specialized approaches and
scaffolds. One of these approaches includes the addition of benzyl triethylammonium chloride
(BTEAC) salt into the polymer solution during the electrospinning fabrication process (known in
the lab as “salt spins”). The goal of this approach is to create nanofibrous scaffolds with smaller
pore sizes that allow for better endothelial cell adhesion without the use of smooth muscle cells.
This provides a sometimes preferred single-sodded model (one cell type instead of two) that allows
for a more straightforward BVM setup and analysis. Adding BTEAC salt into the scaffold requires
performing the standard electrospinning technique using a 75:25 PLGA to chloroform ratio with a
small addition of BTEAC salt. Based on PLGA’s mass, the addition of 3 percent by weight of
BTEAC salt addition was found to be optimal for creating the smallest electrospun fibers. Adding
more than 3 percent by weight led to insignificant changes in fiber diameter. Overall, the addition
of BTEAC salt to PLGA scaffolds provides an effective and reproducible method of creating
nanofiber scaffolds [41].
Along with the specialized electrospinning approach mentioned above, researchers in the
lab have also developed custom aneurysm-shaped molds to create aneurysm BVM scaffolds. To
create these aneurysm geometries, molds with a negative impression of pre-dimensioned CAD
models (Fig. 13) were machined, a stainless-steel mandrel was placed inside the empty molds, and,
finally, melted, water-soluble wax was injected around the mandrels to form casts. The aneurysm
scaffolds were characterized by their overall dimensions and microstructural components and were
later used for cell deposition and vessel cultivation. Results from aneurysm BVM studies
demonstrated feasibility in creating custom aneurysm in vitro models due to appropriate fiber
morphology within the various aneurysm shapes, consistent cell deposition, and successful
cultivation of the aneurysm BVMs [43].
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Figure 13. Design of Electrospun Aneurysm Scaffolds. Saccular, fusiform, and blister
geometries (a-c) [43].

While the electrospinning fabrication process provides adequate polymer structures and
properties in both the standard and more specialized approaches used by tissue engineering lab
researchers, it does require the use of a solvent, and may include additional aspects such as salt
additives or wax molds, which can have significant impacts on biocompatibility.
1.8 Definition and Fundamentals of Biocompatibility
Understanding and evaluating the biocompatibility of a scaffold is paramount, regardless
of which polymer is chosen for the scaffold, how specific electrospinning parameters are set, and
whether any additional complexities are added. Biocompatibility can be defined as the ability of a
material to perform with an appropriate host response in a specific situation [48]. The phrase
‘appropriate host response’ refers to the ability of a material to be harmless to the host tissue and/or
to not fail due to biological mechanisms of the body [49]. To limit any detrimental reactions or lifethreatening complications, host tissue responses must be well characterized and evaluated before
the material is used clinically.
The understanding of biocompatibility has changed over time and, therefore, more detailed
descriptions of it continue to emerge as the medical field grows. With regard to the traditional
medical device field, biocompatibility is described as summarized above, with a focus on the basic
interaction of a material with cells. With regard to the tissue engineering field, biocompatibility is
described as the ability of three-dimensional artificial tissue to be accepted by host defense
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mechanisms upon implantation, while still maintaining functional capacity [50]. In short,
biocompatibility involves how an organism responds to contact with a foreign material and how
that material is affected by the organism. An organism includes either a human or animal and/or a
local tissue or tissue distant from the site of contact [51]. Organism responses include things like
healing, developing a tumor, blood clots, or even death. A foreign material can be fully implanted
into an organism or can be something that simply contacts a mucous membrane, the skin, etc.
Additionally, contact timepoints for a foreign material can be brief (< 24 hours, < 30 days) or
lengthy (> 30 days). Overall, many factors contribute to the biocompatibility of a material and,
therefore, researchers must carefully select appropriate biomaterial(s) to be used when designing a
contact device.
1.8.1 Biocompatibility Background
Before a medical device or biomaterial come in contact with the body—whether directly
or indirectly—researchers must perform extensive biocompatibility testing on the material and/or
device. The material characteristic of biocompatibility distinguishes a biomaterial from other
material types due to its ability to perform its intended function within the human body without
unintentionally harming the body or material.
One harmful effect that may occur if a material or device is not biocompatible is the
potential of triggering the foreign body response. Because the surfaces of most engineered materials
and devices do not hold biological surface markers, the body recognizes them as foreign. Proteins
from the blood react to this foreign article by immediately adsorbing to the surface of it, ultimately
initiating the body’s immune response that attempts to eliminate the material or device. The body’s
foreign body immune response typically involves a cascade of five events: 1) material/device
implant, 2) protein adsorption, 3) cellular recognition, 4) inflammation, and 5) foreign body
response/resolution. Each of these biological steps can involve short-term or long-term effects to
the body. Another harmful effect that may occur is cytotoxicity, or any toxic agent or process that
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kills living cells [52]. Therefore, a critical component of designing a biomaterial is to ensure that
these undesirable responses will not occur.
Although the polymers introduced above—PLGA, PLLA, and PCL—have displayed
acceptable biocompatibility in the field [23][31][35], the electrospinning process requires these
polymers to be dissolved in a solvent for later fabrication of the scaffold. Therefore, the solvents,
along with the polymers, all must be tested for their biocompatibility, as the scaffold (solvent and
polymer) come in direct contact with cells during BVM setups, as described in Section 1.5.
1.8.2

Various Biocompatibility Tests
To assess a material’s biocompatibility, various tests can be performed. As part of the

overall risk management process, there are many factors to consider when choosing which test
procedures to implement, for example, nature, degree, duration, frequency, and conditions of
exposure

to

humans

[48].

Biocompatibility

tests

include

cytotoxicity,

sensitization,

hemocompatibility, pyrogenicity, implantation, genotoxicity, carcinogenicity, reproductive and
developmental toxicity, and degradation assessments. Each medical device is different and
therefore requires unique forms of biological evaluation. Biocompatibility testing of polymers used
in BVM fabrication requires testing the effect of the polymer on cells, as this is the application in
which they are used. Although a variety of biocompatibility tests involve contact with cells, a key
test that all materials are subject to is cytotoxicity.
1.8.2.1 Cytotoxicity Testing
Cytotoxicity is an important test for all medical devices that come in contact with the body.
Cytotoxicity is an in vitro test performed to evaluate whether a medical device causes cell death
via leaching of toxic substances or via direct contact. Primary cytotoxicity experiments include cell
viability testing using dyes that stain for live and dead cells in culture. Cells are then differentiated
based on the ratio of both living to dead cells and assessed further [52]. For novel materials, two
primary methods for cytotoxicity testing are recommended including direct contact and elution
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procedures. Direct contact involves placing a material directly onto the cells and evaluating cell
reaction to the material (i.e., whether cells live or die). Direct contact provides a preliminary insight
into how cells react to certain material types and is an initial qualitative and quantitative assessment
of cytotoxicity. Elution involves leaching all possible toxic substances out of a material and into a
solution that is then used for culturing cells. This technique provides a more thorough qualitative
and quantitative analysis of a material’s effect on cells, as it utilizes cell viability assays to screen
for direct cytotoxic effects of specific compounds [48]. To qualitatively determine cytotoxic
effects, the cells are examined microscopically and assessed for changes in, for example, general
morphology, detachment, cell lysis, and membrane integrity. To quantitatively determine cytotoxic
effects, the ratio of live to dead cells and the number of cells are assessed by objective means. These
methods are utilized to determine the biological response of mammalian cells in vitro using the
appropriate biological parameters [53].
1.9 Biocompatibility Concerns of BVMs
With the materials and solvents required for BVM scaffold fabrication in mind, there are
several concerns with the biocompatibility of these scaffolds. The biocompatibility of polymers
that can be fabricated and customized internally at Cal Poly—PLGA, PLLA, and PCL—are all
well-researched and well-understood, but their combination with corresponding solvents (Table 2)
necessary for scaffold fabrication may impact their effect on cells.

Table 2. The polymers used in BVM fabrication along with their corresponding solvents
utilized during the electrospinning process.
Polymer

Solvent

PLGA

Chloroform

PLGA with salt

Chloroform

PLLA

Chloroform

PCL

Dichloromethane (DCM)
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As Table 2 displays, PLGA, PLGA with salt, and PLLA are dissolved in chloroform.
Chloroform, or CHCl3, is a colorless, volatile, liquid derivative of trichloromethane that was
formerly used as an inhaled anesthetic during surgery. This compound is currently used as a solvent
or a substance that helps other substances dissolve [54]. Chloroform has been studied for its effect
on animals and humans and has demonstrated undesirable toxic effects. Due to its past use as an
anesthetic, chloroform in high concentrations can result in narcosis, anesthesia, and in the most
severe effects of acute exposure, depression of the central nervous system (CNS), and cardiac
sensitization [55]. When studied for its effects on cells, chloroform has also shown concerning
cytotoxic effects in vitro [56]. However, chloroform is also a common electrospinning solvent, and
successful desiccation and rinsing may negate the cytotoxic effects. For example, an in vitro
cytotoxicity study demonstrated the use of chloroform as a solvent in electrospun nanofibers had
no cytotoxicity and was deemed biocompatible [57].
PCL is dissolved in dichloromethane (DCM), or CH2Cl2. Dichloromethane is a colorless,
flammable liquid that exhibits high volatility and stability, but is widely used as an organic solvent.
DCM’s applications include paint removal, cleaning agents, aerosol products, and insecticides.
Although it has many applications, the solvent’s ability to vaporize quickly and remain in the air
makes it a toxic and potentially fatal chemical to humans. Similar to chloroform, this solvent has
presented with inhalation, neurotoxicity, carcinogenicity, and skin irritation dangers [58]. The
dangerous toxicological effects found with chloroform and dichloromethane raise a concern about
their role in the biocompatibility of the polymer solution used in BVM scaffold fabrication,
although similar to chloroform, successful use in electrospun scaffolds has been documented. For
example, electrospun PLGA fibrous scaffolds were dissolved in a mixture solvent containing DCM
and were deemed biocompatible [59].
In addition to the solvents themselves, the addition of benzyl triethylammonium chloride
(BTEAC) to the PLGA solution raises a biocompatibility concern as well. BTEAC is an organic
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compound added to PLGA to decrease fiber diameter, resulting in thinner nanofibers and decreased
pore size. Although thought to be beneficial, the addition of BTEAC into the BVM scaffold solution
adds another component that may impact biocompatibility of the scaffolds. While BTEAC presents
a concern, acute toxicity tests done with BTEAC on small planktonic crustaceans showed toxicity
levels far below what would be required to induce immobilization. Therefore, BTEAC may result
in only minimal toxicity to cells (i.e. not enough to induce cell death) [60]. The various
biocompatibility concerns summarized above demonstrate the need for biocompatibility testing of
the solvents and additives of the BVM polymers.
1.10 Summary and Aims of the Thesis
BVMs continue to be optimized to improve their consistency and utility as preclinical
testing models. As new modifications are made, it is important that biocompatibility testing is done
to evaluate the improved models. BVM scaffolds can be composed of an assortment of polymers
that will contact different cell types, leading to the need for biocompatibility testing of the polymers
prior to their implementation as BVM scaffolds. Many of the lab’s newest scaffolds have not been
fully characterized for biologic interactions, and future scaffold development will benefit from
early-stage biocompatibility testing. The overall goal of this master’s thesis was to evaluate the
biocompatibility of existing and novel BVM scaffolds, with a specific focus on cytotoxicity. To
accomplish this goal, three aims were pursued: 1) Develop the proper and necessary protocols for
cytotoxicity testing, including both direct contact and elution methods, 2) Assess the cytotoxicity
of standard polymers—ePTFE and PLGA—used in the tissue engineering lab, and 3) Assess the
cytotoxicity of recent polymer additions to the lab—PLLA, PCL, and PLGA with salt.
1.10.1

Aim 1: Protocol Development for Cytotoxicity Testing
The first aim of this thesis was to develop the necessary protocols for in vitro cytotoxicity

testing of polymers used in the fabrication of BVMs. This included direct contact and elution
cytotoxicity methods, along with a live/dead assay. The direct contact procedure involved placing
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each electrospun polymer directly onto cells and evaluating the viability and morphology of the
cells at various timepoints. This technique helped to gather preliminary qualitative data on the
cytotoxicity of the different polymer types. The elution procedure involved investigating the
cytotoxicity of the scaffolds through exposure of cells to scaffold elution products. Cell viability
was quantified through a calcein AM and ethidium homdimer-1 (EthD-1) staining assay. These
protocols were developed and optimized in Aim 1.
1.10.2 Aim 2: Biocompatibility of Existing BVM Scaffold Polymers: ePTFE and PLGA
The second aim of this thesis was to implement the newly developed cytotoxicity protocols
to evaluate the biocompatibility of existing polymers, ePTFE and PLGA, used in the tissue
engineering lab. This was done through implementing the direct contact, elution, and cell viability
assays. Results from this aim served as a baseline of acceptable outcomes, since these two polymers
have been used successfully as BVMs for many years.
1.10.3 Aim 3: Biocompatibility of Novel BVM Scaffold Polymers: PLGA with salt, PLLA,
and PCL
The third aim of this thesis was to evaluate the biocompatibility of three novel electrospun
polymers used for BVMs: PLGA with salt, PLLA, and PCL. This was done by implementing the
protocols developed in Aim 1, including direct contact, elution, and cell viability assays.
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CHAPTER 2. AIM 1: PROTOCOL DEVELOPMENT FOR CYTOTOXICITY TESTING
2.1

Introduction
The first aim of this thesis was to develop cytotoxicity protocols for evaluating the

biocompatibility of electrospun polymers used for BVMs. To accomplish this goal, numerous
studies were performed, each of which implemented both direct contact and elution-based methods.
A variety of polymer types were implemented in these studies due to the frequent troubleshooting
of the electrospinner. Issues with the electrospinner necessitated the use of whichever polymer
could be spun effectively at the time. Trial #1 involved a preliminary assessment of cytotoxicity
protocols for PLGA, PLGA with salt, and PLLA. Trial #2 involved performing the cytotoxicity
protocols on ePTFE with a calcein AM and ethidium homodimer-1 cell viability assay. Calcein
AM identifies live cells by their intracellular esterase activity and dyes the cells green. Ethidium
homodimer-1 identifies dead cells by their lack of plasma membrane integrity and dyes the cells
red [61]. Trial #3 involved performing cytotoxicity testing on ePTFE again but included other
sterilization methods to ensure soaking the scaffold in EtOH and rinsing with DPBS (the
sterilization method used in Trials #1 and #2) was an effective form of sterilization. Trial #4
involved cytotoxicity testing on PLGA, PLGA with salt, PLLA, and PCL. Trial #5 involved an
elution test on the experiment’s controls. Trial #6 utilized positive and negative controls while
implementing various timepoints and temperatures to the elution procedure for optimization of the
elution protocol. Trial #7 involved a stain screen with several different stain concentrations and
incubation times to optimize the staining protocol. Trial #8 involved the positive and negative
controls with different extraction ratios for further optimization of the elution protocol.
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2.2

Methods and Results

2.2.1

Cell Culture Procedure
To begin all experiments, mouse fibroblast (3T3) media was prepared following the lab’s

standard operating procedure (SOP) 3010 rev A. Mouse fibroblast (3T3) cells were stored in vials
in a liquid nitrogen dewar. A vial of 3T3s was thawed into 1 T75 and later passed into 1 T225 cell
culture flask according to SOP 3020 rev C and SOP 3021 rev C. Cells were then incubated at 37
degrees Celsius (°C) and 5% Carbon Dioxide (CO2).
2.2.2

Trial #1
This study involved a preliminary assessment of cytotoxicity protocols—developed from

previous work done in the lab—on PLGA, PLGA with salt, and PLLA to ensure efficacy of the
protocols. The direct contact procedure was implemented first, followed by the elution procedure
to gather further qualitative and quantitative data.
2.2.2.1 Cell Seeding Procedure
Direct Contact Cell Seeding
Passage 28 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media, referred to as the “cell solution.” Two mL of 3T3 media was
placed into each well of a 6-well plate (Fig. 14) along with 0.5 mL of the cell solution, resulting in
a final cell seeding density of ~187,500 cells per well or ~19,700 cells/cm2 [62][63]. The 3T3 cells
were counted according to SOP 3040 rev A. The 6-well plate was then placed in the incubator at
37 °C and 5% CO2 for 24 hours.
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Figure 14. Costar 6-well cell culture plate [64].
Elution Cell Seeding
One 35 mm micro-dish (Fig. 15A) and two 8-well micro-slides (Fig. 15B) were used for
cell seeding [65]. Passage 28 3T3 cells at ~90% confluence in 1 T225 cell culture flask were
harvested and resuspended in 20 mL of 3T3 media. Two mL of 3T3 media and 0.5 mL of the cell
solution was placed into the micro-dish, resulting in a final cell seeding density of ~225,000 cells
per well or ~75,000 cells/cm2. Additionally, 0.25 mL of 3T3 media and 0.05 mL of the cell solution
was placed into each well of the micro-slides, resulting in a cell seeding density of ~22,500 cells
per well or ~22,500 cells/cm2. The seeding density was higher in these elution set-ups than in the
direct contact experiment because the optimal cell seeding density was yet to be determined. The
micro-dish and micro-slides were then placed in the incubator at 37 °C and 5% CO2 for 24 hours.

Figure 15. Cell culture plates. A) Micro-dish 35 mm, high glass bottom, B) micro-slide 8-well
[66][65].
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2.2.2.2 Direct Contact Procedure
The scaffold sample used for this trial study was a thin, PLGA trial spin. The scaffold was
cut into 4 pieces and sterilized in sterile 70% Ethanol (EtOH) for 20 minutes. The EtOH was
aspirated out and replaced with Dulbecco’s Phosphate Buffer Solution (DPBS) for 2 minutes to rid
the samples of any residual EtOH. After 2 minutes, the DPBS was aspirated out and forceps were
used to transfer the sterile samples into their corresponding wells. The sterile samples were placed
directly on top of the cells to incubate for various lengths of time before evaluation. Two of the 6
wells were left without polymer (thus containing only 3T3 cells in 3T3 media) to serve as a negative
control. A negative control involves the same experimental procedures except that the treatment is
changed to something that is predicted to have no result [67]. Well plates were observed at 10X
magnification using a white-light fluorescence microscope at 12-, 24-, and 48-hour timepoints and
qualitatively evaluated according to a scale from 0-3. Representative white-light images and their
corresponding toxicity levels on the 0-3 scale are outlined below (Table 3).
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Table 3. Representative white-light images on a scale from 0-3 of toxicity.
Cytotoxicity Scale

Interpretation

0

Noncytotoxic

1

Mildly cytotoxic

2

Moderately cytotoxic

3

Severely cytotoxic

Representative WhiteLight Images

2.2.2.3 Elution Procedure
To begin the elution procedure, 600 mL of water was warmed to 50 °C in a 1000 mL beaker
on a hot plate with a stir bar. Samples of PLGA with salt and PLLA were used for this experiment
(Fig. 16). The PLGA with salt sample was cut into three sections, while the PLLA sample was left
intact, as it was too thin and fragile to section off.
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Figure 16. Trial #1 polymer samples. A) Three cut sections of PLGA with salt, B) PLLA.

The polymer samples were sterilized in conicals of sterile 70% EtOH for 20 minutes and
then subjected to DPBS for 2 minutes to rinse any residual EtOH from the polymers. The samples
were then transferred to conicals of 10 mL 3T3 media and placed into the beaker of water at 50 °C
for 72 hours (Fig. 17). A conical of only 3T3 media (no polymer) was included to serve as a
negative control. After 72 hours, the samples were aseptically removed from the conicals and 0.3
mL of media from each conical was placed into the wells of the micro-slides previously seeded
with cells. The micro-dish was left with only 3T3 cells and warmed 3T3 media from the fridge for
later use as a control during staining. The micro-dish and micro-slides were then placed and left in
the incubator for 24 and 48 hours.
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Figure 17. Trial #1 elution procedure. Conicals of PLGA with salt, PLLA, and 3T3 media
placed in water at 50 °C for 72 hours.

2.2.2.4 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the micro-dish and micro-slides from
the elution procedure were stained and imaged. One of the micro-slides was stained with
Bisbenzimide (BBI), a nuclear stain, and imaged with the widefield fluorescence microscope at
10X magnification following the lab’s SOP 5030 rev B. The other micro-slide was stained with
Trypan Blue to stain any dead cells (Appendix A).
A positive control is a group in an experiment that is not exposed to the experimental
treatment, but receives a treatment with a known result to ensure efficacy of the stain [68]. In this
case, the micro-dish was subjected to 100% EtOH for 20 minutes to serve as a positive control. It
was expected that all cells would die after being subjected to EtOH and therefore demonstrate the
efficacy of the Trypan Blue stain in accounting for dead cells.
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2.2.2.5 Trial #1 Results
Direct Contact Results
White-light images from the Trial #1 direct contact procedure can be found in Appendix
B. The results of Trial #1 are summarized in Table 4. In summary, PLGA did not show cytotoxic
effects at 24 hours and mild cytotoxic effects were observed at 48 hours.

Table 4. Results of Trial #1 direct contact procedure with PLGA. Numbers separated by
commas represent different fields of view.
Timepoint
12 -hour

24-hour

48-hour

Sample

Cytotoxicity Scale

Interpretation

PLGA

0, 0, 0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0, 0, 0

Noncytotoxic

PLGA

0, 0, 0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0, 0, 0

Noncytotoxic

PLGA

1, 1, 1, 0

Mildly cytotoxic

3T3 media (neg. control)

0, 0, 0, 0

Noncytotoxic

Elution Results
The results of the elution procedure (Appendix B) revealed an unsuccessful staining and
imaging protocol. It became evident that a stain able to differentiate between live and dead cells
would be more useful; therefore, BBI was ineffective for this application. No results were taken
from the micro-dish (positive control) because all the cells had died and detached from the bottom
of the well after subjection to 100% EtOH for 20 minutes. No results were gathered from the Trypan
Blue stained micro-slide because no cells were found when counting cells with the hemocytometer
(SOP 3040 rev A).
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2.2.2.6 Trial #1 Issues Noted
Direct Contact Issues Noted
Issues presented by the direct contact procedure in Trial #1 included sterile forceps not
being long enough to transfer the polymer from the conical of DPBS to the wells; therefore, the
DPBS had to be aspirated from the conical and the polymer had to be brought up high enough to
be transferred with shorter sterile forceps. Additionally, there was no replacement of media 24
hours after the cells were seeded and before the polymers were placed into the wells. Furthermore,
due to a high volume of media in the wells, the polymer samples were not sitting directly on top of
the cells.
Elution Issues Noted
Issues presented by the elution procedure in Trial #1 included over-confluency in the
micro-dishes and under-confluency in the micro-slides at 24 hours. Along with this, 600 mL of
water in the beaker was too high, causing the conicals of media to be briefly submerged during the
elution. After 24 hours of the elution, the 600 mL of water from the beaker had evaporated. When
removing the PLGA with salt sample from the conical of media, the polymer broke apart in the
media because it was electrospun months before use and became brittle (Fig. 18). Several issues
were also seen with the staining and imaging protocol. Specifically, BBI and Trypan Blue were
unsuitable stains for this specific application. Additionally, the use of 100% EtOH for 20 minutes
was an ineffective positive control due to observed cell detachment from the well plate.
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Figure 18. Trial #1 PLGA with salt sample broken apart in the media after elution procedure.

2.2.2.7 Trial #1 Next Steps to Try
Direct Contact Next Steps to Try
Due to the direct contact issues described above, the next direct contact experiment
involved longer sterile forceps for transfer of the polymer samples, a replacement of media 24 hours
after cell seeding before polymer placement, and less volume of media in the wells. Less volume
of media would hopefully allow the polymer samples to rest on top of the cells instead of floating
above.
Elution Next Steps to Try
In response to the elution issues described above, 500 mL of water was placed in the beaker
so the conicals would not submerge in the water. Tinfoil was also placed on top of the beaker during
the elution to reduce the evaporation of water. To ensure the water was kept at 50 °C and 500 mL,
the water was evaluated every day throughout the 3-day timepoint. Polymers were freshly spun
before use to overcome the brittleness observed with PLGA. Cell seeding densities were adjusted
accordingly to seed at ~60-70% confluence. Only 6-well plates were utilized, rather than 8-well
plates. Calcein AM and EthD-1 were implemented instead of BBI and Trypan Blue. The positive
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control was created with the use of sterile 70% EtOH for 30-45 seconds instead of 100% EtOH for
20 minutes.
2.2.3

Trial #2
Trial #2 involved performing adjusted cytotoxicity protocols on ePTFE with the calcein

AM and EthD-1 cell viability assay. ePTFE was selected for this trial because it was a wellestablished biocompatible scaffold material and, for this reason, proved useful in the development
of protocols for cytotoxicity testing. The direct contact procedure was implemented first, followed
by the elution procedure to gather further qualitative and quantitative data.
2.2.3.1 Cell Seeding Procedure
Direct Contact Cell Seeding
Passage 34 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Next, 1.5 mL of 3T3 media and 0.5 mL of the cell solution
was placed into each well of a 6-well plate, resulting in a final cell seeding density of ~187,500
cells per well or ~19,700 cells/cm2 [62]. The 6-well plate was then placed in the incubator at 37 °C
and 5% CO2 for 24 hours.
Elution Cell Seeding
Passage 34 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Next, 1.5 mL of 3T3 media was placed into all wells of two
6-well plates and two micro-dishes. One mL of the cell solution was placed into one 6-well plate
and one micro-dish (24-hour timepoints), resulting in a cell seeding density of ~375,000 cells per
well or ~39,500 cells/cm2. Additionally, 0.5 mL of cell solution was placed into the other 6-well
plate and micro-dish (48-hour timepoints), resulting in a cell seeding density of ~187,500 cells per
well or ~19,700 cells/cm2. Half of the cell seeding density was placed into the 48-hour timepoint
well plate because it would be incubating for 24 hours longer than the 24-hour timepoint well plate.
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The 6-well plates and micro-dishes were then placed in the incubator at 37 °C and 5% CO2 for 24
hours.
2.2.3.2 Direct Contact Procedure
ePTFE scaffolds were sterilized in sterile 70% EtOH for 20 minutes and rinsed with DPBS
for 1 minute. One ePTFE scaffold was left in EtOH unrinsed to serve as a positive control. The
ePTFE samples were transferred into their corresponding wells (Fig. 19). Two wells were left
without samples (only 3T3 cells with 3T3 media) to serve as a negative control. The well plate was
then placed in the incubator until being qualitatively evaluated under the white-light fluorescence
microscope at 12-, 24-, and 48-hour timepoints.

Figure 19. Trial #2 direct contact procedure with ePTFE scaffolds.

2.2.3.3 Elution Procedure
Three ePTFE scaffolds were placed in sterile 70% EtOH for 20 minutes and rinsed with
DPBS for 1 minute before being transferred to 10 mL conicals of 3T3 media (Fig. 20A). One
conical was left without a scaffold to serve as a negative control. The conicals were placed in water
at 50 °C for 72 hours (Fig. 20B). The scaffolds were then removed from the media and 2.5 mL of
the eluted media was placed into previously prepared wells of 3T3 cells. The well plates were then
placed in the incubator for 24 and 48 hours.
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Figure 20. Trial #2 elution procedure. A) Three ePTFE scaffolds placed into 10 mL of 3T3
media, B) the conicals placed into water at 50 °C for 72 hours.

2.2.3.4 Staining and Imaging Procedure

After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. Media was aspirated out of the well plates and the microdish was subjected to sterile 70% EtOH for 30-45 seconds to serve as a positive control for the
staining protocol. All wells were rinsed with DPBS, and the live/dead stock stain solution was
created with 5 mL DPBS + 4 uL EthD-1 + 3 uL calcein AM. Next, 0.5 mL of the stain solution was
placed into all wells for 20 minutes before being aspirated out carefully as to not aspirate any cells.
The wells were imaged using the widefield fluorescence microscope. The staining and imaging
procedure was repeated for the 48-hour timepoint wells with a replacement of the eluted media at
24 hours. Due to unclear images and low fluorescence of the stain at 24 hours, a 10 mL DPBS +
12 uL EthD-1 + 10 uL calcein AM stock stain solution was used at 48 hours and 1.5 mL of the stain
was placed onto the wells for 30 minutes.
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2.2.3.5 Trial #2 Results
Direct Contact Results
White-light images from the Trial #2 direct contact procedure can be found in Appendix
C. The results from Trial #2 are summarized in Table 5. ePTFE demonstrated noncytotoxic effects
on 3T3 cells at each timepoint. Additionally, the ePTFE left to soak in EtOH and unrinsed served
as an effective positive control because it demonstrated cell death.
Table 5. Results of Trial #2 direct contact procedure with ePTFE. Numbers separated by
commas represent different fields of view.
Timepoint

12 -hour

24-hour

48-hour

Sample

Cytotoxicity Scale

Interpretation

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Elution Results

White-light images from the Trial #2 elution procedure can be found in Appendix C.
Images taken on the widefield fluorescence microscope are displayed in Figures 21 and 22. Overconfluency was observed in all wells. Along with this, the images demonstrated that ePTFE
scaffolds caused severe cell death, as cells were detaching from the surface of the flask and there
were large areas where no cells were found. The negative and positive controls—warmed 3T3
media and samples subjected to EtOH—were ineffective in providing a basis for comparison
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between cells cultured with the ePTFE eluted media and cells cultured with the controls. The
inefficacy of the controls was due to the positive control not fluorescing dead cells and the negative
controls detecting a high number of dead cells.
Calcein AM

Ethidium Homodimer-1

Failed Positive Control
– EtOH subjection for
30-45 seconds

Failed Negative
Control – 3T3 media
Dead cell

Failed Negative
Control – 3T3 media
warmed in 50 °C water
for 72 hours

ePTFE
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ePTFE

ePTFE

Live cell

Figure 21. Trial #2 widefield fluorescence images of elution procedure at 24-hour timepoint.
10X magnification, 6% power, 500 ms exposure time.

Calcein AM

Ethidium Homodimer-1

Failed Positive
Control – EtOH
subjection for 30-45
seconds

Failed Negative
Control – 3T3 media
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Failed Negative
Control – 3T3 media
warmed in 50 °C
water for 72 hours

ePTFE

ePTFE

ePTFE

Figure 22. Trial #2 widefield fluorescence images of elution procedure at 48-hour timepoint.
10X magnification, 6% power, 500 ms exposure time.
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2.2.3.6 Trial #2 Issues Noted
Direct Contact Issues Noted
A notable issue from the Trial #2 direct contact procedure was that the positive control well
containing the unrinsed ePTFE scaffold subjected to EtOH still contained confluent, live cells.
Additionally, the negative control of only 3T3 media suggested that cell death was due to overconfluency rather than cytotoxic factors, which could result in false conclusions.
Elution Issues Noted
Over-confluency in all wells was also noted as an issue with the Trial #2 elution procedure.
Severe cell death of cells immersed in the ePTFE eluted media was observed and determined by
cell detachment from the flask surface as well as large areas where no cells were found. However,
it was not possible to attribute the cell death to ePTFE, due to the failure of the negative controls.
Observed cell death could have been attributed to the media not completely cooling from 50 °C to
37 °C before being placed onto the cells. The 24-hour widefield fluorescence images displayed an
unsuccessful staining and imaging protocol due to unclear images and low florescence of cells.
Adjustments were made to the protocol for the 48-hour timepoints: 10 mL DPBS + 12 uL EthD-1
+ 10 uL calcein AM stock stain solution, 1.5 mL of stain placed into each well, and a 30-minute
incubation time. While images looked clearer, the positive control was still unsuccessful in
demonstrating cell death. In addition, the 48-hour timepoint images displayed a significant number
of dead cells in warmed 3T3 media from the fridge, which was unexpected.
2.2.3.7 Trial #2 Next Steps to Try
Direct Contact Next Steps to Try
Due to the issues described above, the next direct contact procedure implemented a longer
soak of the polymer in EtOH before placing it onto cells for the positive control, as well as lower
cell seeding densities.
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Elution Next Steps to Try

Due to the issues described above, the scaffolds were rinsed more thoroughly in DPBS
after being sterilized in EtOH. In response to the previously unsuccessful positive control, the
micro-dish was subjected to 2 mL of 100% methanol for 20 minutes instead of the previously used
100% EtOH for 20 minutes and sterile 70% EtOH for 30-45 seconds. This decision was based on
knowledge gained from classes taken during protocol development. The cell seeding density was
decreased to mitigate the observed over-confluency and cell death seen in warmed 3T3 media from
the fridge. Regarding the staining and imaging protocol, to get clearer images, the power was
increased, and the exposure time was decreased on the widefield fluorescence microscope.
Additionally, to ensure the efficacy of scaffold sterilization, another round of ePTFE cytotoxicity
testing involving other forms of sterilization methods was performed.
2.2.4

Trial #3
Trial #3 involved performing cytotoxicity testing on ePTFE again but included other

sterilization methods to ensure efficacy of the sterilization method used in Trials #1 and #2. This
trial included only an elution procedure. A direct contact procedure was not performed because this
trial was focused on optimizing the elution procedure and sterilization parameters.
2.2.4.1 Cell Seeding Procedure
Passage 28 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Next, 1.5 mL of 3T3 media was placed into four 6-well plates
and two micro-dishes. Additionally, 0.5 mL of the cell solution was placed into two of the 6-well
plates and one micro-dish (24-hour timepoints), resulting in a cell seeding density of ~187,500 cells
per well or ~19,700 cells/cm2. Next, 0.25 mL of cell solution was placed into the other 6-well plates
and micro-dish (48-hour timepoints), resulting in a cell seeding density of ~93,750 cells per well
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or ~9,900 cells/cm2. The 6-well plates and micro-dishes were then placed in the incubator for 24
hours at 37 °C and 5% CO2.
2.2.4.2 Elution Procedure
Three ePTFE scaffolds were subjected to different forms of sterilization. ePTFE scaffold
#1 was sterilized by being placed onto fittings, soaked in a conical of sterile 70% EtOH for 20
minutes, and aseptically flushed with DPBS three times transmurally and transluminally. Sterile
gloves and forceps were utilized to ensure a sterile environment. The fittings were cut off and the
scaffold was placed into a 10 mL conical of 3T3 media. ePTFE scaffold #2 was sterilized via
autoclaving and placed into a 10 mL conical of 3T3 media. ePTFE scaffold #3 was sterilized using
the method from Trial #1 and #2 – soaked in a conical of sterile 70% EtOH for 20 minutes and then
thoroughly rinsed in DPBS for 1 minute. This scaffold was placed into another 10 mL conical of
3T3 media. A conical of 10 mL 3T3 media (no scaffold) was included to serve as a negative control.
All conicals were placed into the water bath at 50 °C for 72 hours. After 72 hours, the scaffolds
were removed, and 1.5 mL of the eluted media was added to the cells. The well plates were then
placed into the incubator for 24 and 48 hours.
2.2.4.3 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. The media was aspirated out of the well plates and the
micro-dish was subjected to methanol for 20 minutes to serve as a positive control for the staining
protocol. All wells were rinsed with DPBS, and the live/dead stock stain solution was made of 10
mL DPBS + 12 uL EthD-1 + 10 uL calcein AM. Next, 1.5 mL of the stain solution was placed into
each well for 30 minutes and aspirated out carefully as to not aspirate any cells. The wells were
then imaged using the widefield fluorescence microscope. This staining and imaging procedure
was repeated for the 48-hour timepoint wells with a replacement of the eluted media at 24 hours.
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2.2.4.4 Trial #3 Results
White-light images from the Trial #3 elution procedure illustrated noncytotoxic effects at
24-hours and mild cytotoxic effects at 48-hours with each sterilization method and the negative
control of 3T3 media warmed to 50 °C for 72 hours. The other negative control (warmed 3T3 media
from the fridge) was effective in demonstrating noncytotoxic effects, while the positive control
(methanol subjection) was effective in demonstrating severe cytotoxic effects. Images can be found
in Appendix D and results are summarized in Table 6.

Table 6. Results of Trial #3 elution procedure with ePTFE including various sterilization
methods. Numbers separated by commas represent different fields of view.
Timepoint

24-hour

48-hour

Form of Sterilization

Cytotoxicity
Scale

Interpretation

Soak in EtOH and flush with DPBS

0, 0

Noncytotoxic

Autoclave

0, 0

Noncytotoxic

Soak in EtOH and thoroughly rinse with DPBS

0, 0

Noncytotoxic

3T3 media warmed to 50 °C for 72 hours (neg.
control)

0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Methanol (pos. control)

3, 3

Severely
cytotoxic

Soak in EtOH and flush with DPBS

1, 1

Mildly cytotoxic

Autoclave

1, 1

Mildly cytotoxic

Soak in EtOH and thoroughly rinse with DPBS

1, 1

Mildly cytotoxic

3T3 media warmed to 50 °C for 72 hours (neg.
control)

1, 1

Mildly cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Methanol (pos. control)

3, 3

Severely
cytotoxic
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Results from the widefield fluorescence images (Fig. 23, 24) illustrated that methanol for
20 minutes acted as an effective positive control for demonstration of cell death. Over-confluency
was still observed in all wells. The fluorescence stain was much brighter than it had been in previous
trials due to increased proficiency with the widefield fluorescence microscope and the increase in
power from 6% power to 12% power. ePTFE was no longer demonstrating cell death and each
sterilization method was effective and comparable. This elution procedure reinforced that each
sterilization technique demonstrated low cell death; therefore, it was concluded that soaking the
scaffold in EtOH and thoroughly rinsing with DPBS was an effective form of sterilization.
Calcein AM

Ethidium Homodimer-1

Effective Positive
Control –
methanol
subjection for 20
minutes

Effective Negative
Control – 3T3
media

Effective Negative
Control – 3T3
media warmed in
50 °C water for 72
hours
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ePTFE scaffold
soaked in EtOH
and flushed with
DPBS

ePTFE scaffold
autoclaved

ePTFE soaked in
EtOH and
thoroughly rinsed
with DPBS

Figure 23. Trial #3 widefield fluorescence images of 24-hour timepoint elution procedure.
10X magnification, 12% power, 500 ms exposure time.
Calcein AM

Ethidium Homodimer-1

Effective Positive
Control –
methanol
subjection for 20
minutes
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Effective
Negative Control
– 3T3 media

Effective
Negative Control
– 3T3 media
warmed in 50 °C
water for 72
hours

ePTFE scaffold
soaked in EtOH
and flushed with
DPBS

ePTFE scaffold
autoclaved
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ePTFE soaked in
EtOH and
thoroughly rinsed
with DPBS

Figure 24. Trial #3 widefield fluorescence images of 48-hour timepoint elution procedure.
10X magnification, 12% power, 500 ms exposure time.

2.2.4.5 Trial #3 Issues Noted
Over-confluency was still a notable issue from Trial #3. Future studies did not utilize the
flushing with DPBS or autoclave sterilization techniques because polymers were spun on a flat
sheet collector (mandrel collector was out for maintenance). Another issue was that no successfully
established, positive control had been utilized to ensure cytotoxic substances were effectively being
leached out of samples at an extraction condition of 50 °C for 72 hours.
2.2.4.6 Trial #3 Next Steps to Try
Due to the issues described above, the cell seeding density was decreased further. The
sterilization technique of soaking the polymer in EtOH and thoroughly rinsing in DPBS was
confirmed as an acceptable sterilization method. A longer rinsing time was implemented to ensure
all residual EtOH was removed from the polymer. A sample of sterile, powder-free latex glove was
used in the following elution procedures to serve as a positive control for the leaching of cytotoxic
substances during the elution procedure.
2.2.5

Trial #4
All previous study takeaways were implemented in Trial #4, which involved cytotoxicity

testing on PLGA (solvent: chloroform), PLGA with salt (solvent: chloroform), PLLA (solvent:
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chloroform), and PCL (solvent: DCM). These polymer types were used to gather preliminary
biocompatibility insight on these scaffold materials. Sterile, powder-free latex gloves were used as
a positive control, as it has been shown that they leach out toxins from the polymer sample and kill
cells that are cultured with the eluted media [69]. This trial included only an elution procedure. No
direct contact procedure was performed because the elution procedure was still in need of
optimization.
2.2.5.1 Cell Seeding Procedure
Passage 28 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Two mL of 3T3 media was placed into each well of six 6well plates and two micro-dishes. Next, 0.3 mL of the cell solution was placed into three of the 6well plates and one micro-dish (24-hour timepoints), resulting in a cell seeding density of ~112,500
cells per well or ~11800 cells/cm2. Additionally, 0.15 mL of cell solution was placed into the other
6-well plates and micro-dish (48-hour timepoints), resulting in a cell seeding density of ~56,250
total cells per well or ~6000 cells/cm2. The 6-well plates and micro-dishes were then placed in the
incubator for 24 hours at 37 °C and 5% CO2.
2.2.5.2 Elution Procedure
To begin the elution procedure for Trial #4, each electrospun polymer and a powder-free
latex glove sample were sterilized in a conical of sterile 70% EtOH for 20 minutes and then rinsed
thoroughly with DPBS for 1 minute. The samples were transferred to separate conicals containing
15 mL of 3T3 media. In addition, 15 mL of 3T3 media (negative control) and 15 mL of 3T3 media
with the sample of sterile, powder-free latex glove (positive control) (Fig. 25A) were included in
the trial. All conicals were placed in water at 50 °C for 72 hours (Fig. 25B).
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Figure 25. Trial #4 elution preparation. A) Sterile, powder-free latex glove (positive control),
B) conicals placed in water at 50 °C for 72 hours.

After 72 hours, the samples were aseptically removed from the conicals (Fig. 26A) and the
eluted media (Fig. 26B) was placed into the fridge to cool. Once cooled, the conicals were warmed
in the water bath to 37 °C and 2 mL of the eluted media was placed into corresponding wells of the
6-well plates. The well plates were placed in the incubator for 24 and 48 hours.

Figure 26. Trial #4 samples after elution. A) Samples of polymer removed from the conicals
after being placed in water at 50 °C for 72 hours, B) the resulting eluted media before being
placed onto the cells.
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2.2.5.3 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. The media was aspirated out of the well plates and the
micro-dish was subjected to methanol for 20 minutes to serve as a positive control for the staining
protocol. All wells were rinsed with DPBS, and the live/dead stock stain solution was made with
30 mL DPBS + 36 uL EthD-1 + 30 uL calcein AM. Additionally, 1.5 mL of the stain solution was
placed into each well for 30 minutes and aspirated out carefully as to not aspirate the cells. The
wells were then imaged using the widefield fluorescence microscope. This staining and imaging
procedure was repeated for the 48-hour timepoint wells with a replacement of the eluted media at
24 hours.
2.2.5.4 Trial #4 Results
White-light images from Trial #4 at 24 hours (Appendix E) displayed variability between
each polymer. Specifically, PLLA, PLGA, and PLGA with salt illustrated moderate cytotoxic
effects while PCL scaffold and flat sheet samples illustrated mild cytotoxicity. These results are
summarized in Table 7. The negative controls – 3T3 media and 3T3 media that was warmed to 50
°C for 72 hours – were successful in demonstrating limited cell death. The positive control—
powder-free latex glove eluted media—was successful in invoking cell death. At 48 hours, whitelight images (Appendix E) displayed insufficient cell confluence as well as dead cells with all
images other than the negative control of warmed 3T3 media from the fridge. Additionally, while
the negative control of 3T3 media displayed limited cell death, the negative control of 3T3 media
warmed to 50 °C for 72 hours displayed significant cell death. The positive control of powder-free
latex glove eluted media also presented the expected cell death.
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Table 7. Results of Trial #4 elution procedure. Numbers separated by commas represent
different fields of view.
Timepoint

24-hour

48-hour

Sample

Cytotoxicity
Scale

Interpretation

PLLA

2, 1

Moderately cytotoxic

PLGA

2, 2

Moderately cytotoxic

PLGA with salt

2, 1

Moderately cytotoxic

PCL scaffold

1, 1

Mildly cytotoxic

PCL flat sheet 210310

1, 1

Mildly cytotoxic

PCL flat sheet 210215

1, 1

Mildly cytotoxic

3T3 media warmed to 50 °C for 72
hours (neg. control)

0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Latex glove (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

PLLA

0, 2

Mildly cytotoxic

PLGA

0, 3

Moderately cytotoxic

PLGA with salt

2, 3

Severely cytotoxic

PCL scaffold

3, 3

Severely cytotoxic

PCL flat sheet 210310

3, 3

Severely cytotoxic

PCL flat sheet 210215

3, 3

Severely cytotoxic

3T3 media warmed to 50 °C for 72
hours (neg. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Latex glove (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

Widefield fluorescence images from Trial #4 at 24 hours (Fig. 27) demonstrated limited
cell death for all polymer types. The controls—subjection to methanol for 20 minutes, warmed 3T3
media from the fridge, 3T3 media warmed to 50 °C for 72 hours, and powder-free latex glove eluted
media—seemed to have worked effectively at 24 hours. In contrast, at 48 hours (Fig. 28), much
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more cell death was observed across wells. The positive control of powder-free latex glove eluted
media displayed no cells because all cells had died, detached from the well plate, and were aspirated
during the staining and imaging protocol. The negative control of 3T3 media warmed to 50 °C for
72 hours was ineffective because it displayed almost no cells. This result was contradictory to prior
results seen with the negative control at these same parameters. This result suggested inconsistency
with the elution procedure’s extraction condition of 50 °C for 72 hours.
Calcein AM

Ethidium Homodimer-1

Effective
Positive Control
– methanol
subjection for
20 minutes

Effective
Negative
Control – 3T3
media

Effective
Negative
Control – 3T3
media warmed
to 50 °C for 72
hours
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Effective
Positive Control
– powder-free
latex glove
eluted media

PLLA

PLGA

PLGA with salt

55

PCL spun on
210315

PCL spun on
210215

PCL scaffold

Figure 27. Trial #4 widefield fluorescence images of 24-hour timepoint elution procedure.
10X magnification, 50% power, 1 ss exposure time.
Calcein AM

Ethidium Homodimer-1

Effective Positive
Control –
methanol
subjection for 20
minutes

56

Effective
Negative Control
– 3T3 media

Failed Negative
Control – 3T3
media warmed to
50 °C for 72
hours

Effective Positive
Control –
powder-free latex
glove eluted
media

PLLA

57

PLGA

PLGA with salt

PCL spun on
210315

PCL spun on
210215

58

PCL scaffold

Figure 28. Trial #4 widefield fluorescence images of 48-hour timepoint elution procedure.
10X magnification, 12% power, 500 ms exposure time.

2.2.5.5 Trial #4 Issues Noted
An issue during Trial #4 included using different cell seeding densities for the 24- and 48hour timepoints (i.e., half of the cell seeding density was used for the 48-hour timepoint because it
would be incubated for 24 hours longer). Additionally, when removing the PLGA and PLGA with
salt samples from their conicals after the elution, the polymers broke down and sunk to the bottom,
leaving polymer debris (Fig. 29). This, unfortunately, caused debris to be placed onto the cells with
the media. Another issue noted was the discoloration of the PLGA conical compared to other
conicals (yellow-ish rather than pink) when removed from the 50 °C water. This suggested the
eluted media had become rather acidic after the elution procedure. A critical issue found was the
inconsistency of the 50 °C for 72 hours extraction condition. In past trials, 3T3 media warmed to
50 °C for 72 hours illustrated confluent, live cells; however, this trial’s negative control
demonstrated significant cell death within 48 hours.
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Figure 29. Trial #4 PLGA and PLGA with salt conicals after being removed from the 50 °C
water for 72 hours. The polymer broke down in the conical when being removed. The PLGA
conical is also discolored, compared to the other polymer conicals.

2.2.5.6 Trial #4 Next Steps to Try
Due to the previously described issues, the same cell seeding density was to be
implemented for the 24- and 48-hour studies, instead of seeding half into the 48-hour studies.
Additionally, an experiment with only the elution controls, what eventually became Trial #5, was
to be performed to ensure that these controls were working properly.
2.2.6

Trial #5
Trial #5 involved an elution test with only the negative and positive controls to ensure

efficacy of the controls and elution extraction conditions. The negative controls included 3T3 cells
cultured with warmed 3T3 media from the fridge as well as 3T3 media that had been warmed to 50
°C for 72 hours. The positive control included 3T3 cells cultured with media that was eluted by a
powder-free latex glove warmed to 50 °C for 72 hours. This study included only an elution
procedure. No direct contact was performed because the trial was focused on the elution procedure
and controls.
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2.2.6.1 Cell Seeding Procedure
Passage 28 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Two mL of 3T3 media was placed into each well of two 6well plates. Next, 0.3 mL of the cell solution was then placed into the 6-well plates, resulting in a
cell seeding density of ~112,500 total cells per well or ~11,800 cells/cm2. The 6-well plates were
then placed in the incubator for 24 hours.
2.2.6.2 Elution Procedure
To begin the Trial #5 procedure, two conicals were prepared, each with 10 mL of 3T3
media. The negative control included 3T3 media with no sample. The positive control included a
sterile, powder-free latex glove sample in the media. The conicals were warmed to 50 °C for 72
hours. After 72 hours, 3T3 cells were cultured with warmed 3T3 media from the fridge, the 3T3
media warmed to 50 °C for 72 hours, and the sterile, powder-free latex glove eluted media warmed
to 50 °C for 72 hours. The well plates were then incubated for 24 and 48 hours.
2.2.6.3 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. The media was aspirated out of the well plates and rinsed
with DPBS for 1 minute. Next, 1.5 mL of a live/dead stock stain solution consisting of 30 mL of
DPBS + 36 uL EthD-1 + 30 uL calcein AM was placed into each well for 30 minutes and aspirated
out carefully as to not aspirate any of the cells. The wells were imaged immediately using the
widefield fluorescence microscope. This staining and imaging procedure was repeated for the 48hour timepoint wells.
2.2.6.4 Trial #5 Results
Trial #5 results illustrated confluent, live cells cultured with warmed 3T3 media from the
fridge; however, large gaps between cells were observed with the cells cultured in 3T3 media
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warmed to 50 °C for 72 hours and the latex glove eluted media. White-light images at 24 and 48
hours (Appendix F) displayed and confirmed significant cell death and detachment from the well
plate when cultured with 3T3 media that had been warmed to 50 °C for 72 hours. These results are
summarized in Table 8. This result further indicated and reinforced that the elution extraction
conditions of 50 °C for 72 hours was suboptimal.

Table 8. Results of Trial #5 elution procedure. Numbers separated by commas represent
different fields of view.
Timepoint

24-hour

48-hour

Controls

Cytotoxicity
Scale

Interpretation

3T3 media

0, 0

Noncytotoxic

Latex glove

2, 2

Moderately cytotoxic

3T3 media warmed to 50 °C for 72 hours

2, 1

Moderately cytotoxic

3T3 media

0, 0

Noncytotoxic

Latex glove

3, 2

Severely cytotoxic

3T3 media warmed to 50 °C for 72 hours

2, 2

Moderately cytotoxic

The negative control of 3T3 cells cultured in warmed 3T3 media from the fridge displayed
consistent cell morphology and ~90% confluence (Fig. 30, 31). Meanwhile, the negative control of
cells cultured in 3T3 media that had been warmed to 50 °C for 72 hours displayed inconsistent cell
morphology and ~60% confluence, which was unexpected. The positive control of cells cultured
with media previously subjected to sterile, powder-free latex glove eluted media demonstrated
significant cell death and detachment from the well plate, which was expected.
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Calcein AM

Ethidium Homodimer-1

Effective
Negative
Control –
warmed 3T3
media

Effective
Negative
Control –
warmed 3T3
media

Failed Negative
Control – 3T3
media at 50 °C
for 72 hours

Failed Negative
Control – 3T3
media at 50 °C
for 72 hours
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Effective
Positive
Control –
Powder-free
latex glove
eluted media at
50 °C for 72
hours

Effective
Positive
Control –
powder-free
latex glove
eluted media at
50 °C for 72
hours

Figure 30. Trial #5 widefield fluorescence images of 24-hour timepoint elution procedure.
10X magnification, 12% power, 500 ms exposure time.
Calcein AM

Ethidium Homodimer-1

Effective
Negative
Control – 3T3
media

Effective
Negative
Control – 3T3
media
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Failed
Negative
Control – 3T3
media at 50 °C
for 72 hours

Failed
Negative
Control – 3T3
media at 50 °C
for 72 hours

Effective
Positive
Control –
Powder-free
latex glove
eluted media at
50 °C for 72
hours

Effective
Positive
Control –
Powder-free
latex glove
eluted media at
50 °C for 72
hours

Figure 31. Trial #5 widefield fluorescence images of 48-hour timepoint elution procedure.
10X magnification, 12% power, 500 ms exposure time.
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2.2.6.5 Trial #5 Issues Noted
A notable issue from Trial #5 was the unsuccessful elution method of warming the
extraction subjects to 50 °C for 72 hours. This timepoint and temperature was ineffective in safely
leaching all toxic substances from the samples without harming the 3T3 elution medium.
2.2.6.6 Trial #5 Next Steps to Try
Due to the issue noted above, new extraction conditions of the elution procedure were to
be tested to determine the optimal temperature and time combination. The optimal combination
should leach all toxic substances from the extraction samples without negatively impacting the
culture medium in which the samples are eluted.
2.2.7

Trial #6
This trial tested new temperature and timepoints for the elution procedure—50 °C for 24

hours, 50 °C for 72 hours, 37 °C for 24 hours, and 37 °C for 72 hours—to determine the optimal
elution method. These extraction conditions were determined based on recommendations by the
FDA document ISO10993 - Biological Evaluation of Medical Devices [53]. The negative controls
included 3T3 cells cultured with warmed 3T3 media from the fridge and 3T3 media that had been
warmed to either 50 or 37 °C for 24 or 72 hours, although it was noted that based on prior trials the
3T3 media at 50 °C may or may not actually serve as an effective negative control. The positive
control included 3T3 cells cultured with media eluted with a sterile, powder-free latex glove
warmed to either 50 or 37 °C for 24 or 72 hours. An extraction ratio of 6 cm2/mL for samples
thinner than 0.5 mm was implemented to ensure use of proper, consistent, and successful extraction
ratio for toxins to leach from the sample [70]. This study included only an elution procedure. No
direct contact procedure was performed because the trial was focused on the elution procedure.
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2.2.7.1 Cell Seeding Procedure
Passage 31 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Two mL of 3T3 media was placed into each well of eight 6well plates and two micro-dishes. Next, 0.3 mL of the cell solution was placed into each well of
the 6-well plates and micro-dishes, resulting in a cell seeding density of ~112,500 cells per well or
~11,800 cells/cm2. The 6-well plates and micro-dishes were then placed in the incubator for 24
hours.
2.2.7.2 Elution Procedure
As introduced above, different elution temperatures and timepoints were implemented in
this trial as outlined in Table 9. Additionally, an extraction ratio of 6 cm2/mL for samples thinner
than 0.5 mm was implemented to ensure consistency amongst samples and to ensure use of the
proper extraction ratio for toxins to leach from the sample successfully.
Table 9. Trial #6 elution controls at each different extraction condition.
Control

Temperature (°C)
37

3T3 Media
50

37
5.4 cm2 latex
sample
50

37
60 cm2 latex
sample
50
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Time (hours)
24
48
24
48
24
48
24
48
24
48
24
48

Conicals of 10 mL 3T3 media were prepared for each extraction condition listed in Table
9, with either no sample (only 3T3 media), a 5.4 cm2 sample of a sterile, powder-free latex glove
(size of the lab’s standard BVM scaffolds), or a 60 cm2 sample of a sterile, powder-free latex glove
(recommended extraction ratio) (Fig. 32A). Each of these conicals were then subjected to the
temperature and timepoint combinations described above. The conicals warmed to 50 °C were
placed in a water bath at 50 °C while the conicals warmed to 37 °C were placed in the incubator.
After the 24- and 72-hour elution procedures, the samples were removed from the conicals (Fig.
32B) and 3T3 cells were cultured with the eluted media for 24 and 48 hours.

Figure 32. Trial #6 elution procedure. A) Latex samples, B) samples removed from the
conicals before media was placed onto cells.

2.2.7.3 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. The media was aspirated out of the well plates and the
micro-dish was subjected to methanol for 20 minutes to serve as a positive control for the staining
protocol. All wells were rinsed with DPBS, and the live/dead stock stain solution was made with
30 mL DPBS + 36 uL EthD-1 + 30 uL calcein AM. Next, 1.5 mL of the stain was placed into all
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wells for 30 minutes and aspirated out carefully as to not aspirate the cells. Wells were then
immediately imaged after using the widefield fluorescence microscope. This staining and imaging
procedure was repeated for the 48-hour well plates.
2.2.7.4 Trial #6 Results
Results from Trial #6 illustrated cell detachment from the surface of the flask and large
gaps between cells with 3T3 media and latex glove eluted media subjected to 50 °C for 24 and 72
hours and 37 °C for 72 hours. Meanwhile, cells cultured with 3T3 media and 5.4 cm2 latex glove
sample eluted media warmed to 37 °C for 24 hours illustrated confluent, live cells while the 60 cm2
latex glove sample eluted media illustrated severe cell death. White-light images from Trial #6 are
found in Appendix G and results are summarized in Table 10. The optimal extraction condition
was 37 °C for 24 hours due to its resulting noncytotoxic 3T3 media and severely cytotoxic 60 cm2
latex-eluted media. Alternately, the 5.4 cm2 latex sample (standard size of the lab’s BVMs) was
noncytotoxic at 24 and 48 hours. This observed noncytotoxic effect may be due to the sample being
too small to sufficiently leach out enough toxins to cause cell death.
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Table 10. Results of Trial #6 elution procedure. Numbers separated by commas represent
different fields of view.
Timepoint

Extraction
Condition

50 °C, 24 hours

50 °C, 72 hours
24 hours
37 °C, 24 hours

37 °C, 72 hours

50 °C, 24 hours

50 °C, 72 hours
48 hours
37 °C, 24 hours

37 °C, 72 hours

Control

Cytotoxicity
Scale

Interpretation

3T3 media

1, 1

Mildly cytotoxic

5.4 cm2 Latex

1, 1

Mildly cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

1, 2

Moderately cytotoxic

5.4 cm2 Latex

2, 2

Moderately cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

0, 0

Noncytotoxic

5.4 cm2 Latex

0, 0

Noncytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

0, 3

Moderately cytotoxic

5.4 cm2 Latex

2, 2

Moderately cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

2, 2

Moderately cytotoxic

5.4 cm2 Latex

2, 2

Moderately cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

2, 2

Moderately cytotoxic

5.4 cm2 Latex

3, 2

Severely cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

0, 0

Noncytotoxic

5.4 cm2 Latex

0, 0

Noncytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic

3T3 media

0, 2

Mildly cytotoxic

5.4 cm2 Latex

1, 2

Moderately cytotoxic

60 cm2 Latex

3, 3

Severely cytotoxic
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2.2.7.5 Trial #6 Issues Noted
The most notable issue seen with Trial #6 was an ineffective use of the stain. After applying
the stain to the wells and incubating for 30 minutes, all 3T3 cells detached from the bottom of the
well plates (Fig. 33), resulting in well plates that were unable to be imaged under the widefield
fluorescence microscope due to unidentifiable cells.

Dead cells

Figure 33. Trial #6 unsuccessful staining protocol. The far left and far right wells of the well
plate display 3T3 cells that have completely detached from the bottom of the well plate
(identified by the arrow) after being subjected to stain for 30 minutes.

2.2.7.6 Trial #6 Next Steps to Try
Due to the issues noted above, a new staining protocol was developed to ensure cells no
longer detached from the bottom of the well plate after being subjected to the stain.
2.2.8

Trial #7
This trial involved a stain screen with several different concentrations of the stain along

with incubation times. It was evident from Trial #6 that the staining protocol was lifting the cells
from the bottom of the flask and therefore fluorescence images were unobtainable. New stain was
purchased because this issue was not noted in prior trials and the previously used stain may have
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expired. The goal of this trial was to optimize the staining protocol and ensure there was no
detachment of cells from the bottom of the flask.
2.2.8.1 Cell Seeding Procedure
Passage 32 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Two mL of 3T3 media was placed into each well of two 6well plates. Next, 0.3 mL of the cell solution was placed into each well of the 6-well plates, resulting
in a cell seeding density of ~112,500 cells per well or ~11,800 cells/cm2. The 6-well plates were
then placed in the incubator for 24 hours.
2.2.8.2 Staining and Imaging Procedure
After 24 hours of incubation, the media was aspirated out of the well plates and all wells
were rinsed with DPBS. Three different live/dead stock stain solutions were made with the newly
purchased stain (Table 11). Next, 1.5 mL of each different stain concentration was placed into
corresponding wells. One well plate was incubated for 5 – 10 minutes and the other well plate for
20 – 25 minutes. After the incubation time, the stain was aspirated and wells were imaged
immediately using the widefield fluorescence microscope to determine which combination of
incubation time and concentration of stain resulted in the most effective staining protocol (i.e., clear
and intense fluorescence images with no cell detachment from the well plate).

Table 11. Trial #7 stock stain concentrations.
Stain Concentration
10 mL DPBS + 12 uL EthD-1 + 10 uL calcein AM
10 mL DPBS + 20 uL EthD-1 + 10 uL calcein AM
10 mL DPBS + 12 uL EthD-1 + 3 uL calcein AM
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2.2.8.3 Trial #7 Results
Widefield fluorescence images from the Trial #7 stain screen (Fig. 34) illustrated clear and
intense images with each different stock stain concentration. Since the stock stain solution of 10
mL DPBS + 12 uL EthD-1 + 3 uL calcein AM had the lowest concentration of stain in the solution
and was still able to produce a bright and distinguishable image for both stains, this stock stain
concentration was deemed optimal. However, after 20 – 25 minutes of incubating the stain, cells
began to lift off the surface of the flask. This was not observed with the 5 – 10-minute incubation
time. Therefore, it was determined that 5 – 10 minutes of incubating the stain was the optimal
incubation time.

Incubation Time /

Calcein AM

Ethidium Homodimer-1

Concentration
5 – 10 minutes
incubation time
10 mL DPBS +
12 uL EthD-1
+ 10 uL calcein
AM

5 – 10 minutes
incubation time
10 mL DPBS +
20 uL EthD-1
+ 5 uL calcein
AM
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5 – 10 minutes
incubation time
10 mL DPBS +
12 uL EthD-1
+ 3 uL calcein
AM

15 – 20
minutes
incubation time
10 mL DPBS +
12 uL EthD-1
+ 10 uL calcein
AM

15 – 20
minutes
incubation time
10 mL DPBS +
20 uL EthD-1
+ 5 uL calcein
AM

15 – 20
minutes
incubation time
10 mL DPBS +
12 uL EthD-1
+ 3 uL calcein
AM

Figure 34. Trial #7 widefield fluorescence images of stain screen.
10X magnification, 3% power, 500 ms exposure time.
2.2.8.4 Trial #7 Issues Noted
No issues were noted with Trial #7.
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2.2.8.5 Trial #7 Next Steps to Try
The Trial #7 stain screen determined that incubation of the stain for 5 – 10 minutes with a
stock stain concentration of 10 mL DPBS + 12 uL EthD-1 + 3 uL calcein AM was to be
implemented in future staining and imaging procedures. As compared with prior trials where 10
mL DPBS + 12 uL EthD-1 + 10 uL calcein AM of the stain solution was incubated on the cells for
30 minutes. ThermoFisher Scientific customer support suggested that the stain used in past trials
may have expired after a year of use and that excessive use of calcein AM (containing DMSO)
could be contributing to the observed cell detachment from the surface of the flask.
2.2.9

Trial #8
The optimal extraction condition of 37 °C for 24 hours was implemented in this trial.

Various extraction ratios were tested by implementing different sample sizes of sterile, powderfree latex glove. The goal of this trial was to determine if there was a threshold of sample size
where cell death became evident. This trial included only an elution procedure.
2.2.9.1 Cell Seeding Procedure
Passage 32 3T3 cells at ~90% confluence in 1 T225 cell culture flask were harvested and
resuspended in 24 mL of 3T3 media. Two mL of 3T3 media was placed into each well of four 6well plates and two micro-dishes. Additionally, 0.3 mL of the cell solution was placed into each
well of the 6-well plates and micro-dishes, resulting in a cell seeding density of ~112,500 cells per
well or ~11,800 cells/cm2. The 6-well plates and micro-dishes were then placed in the incubator for
24 hours.
2.2.9.2 Elution Procedure
To begin Trial #8, six conicals were prepared with 10 mL of 3T3 media. The negative
control included 3T3 media with no sample. The positive controls included media eluted with
samples of a sterile, powder-free latex glove in various sizes: 6, 15, 30, 45, and 60 cm2. The
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prepared conicals were then warmed in the incubator to 37 °C for 24 hours. After 24 hours, the
samples were removed from the conicals, leaving only the eluted media. 3T3 cells were cultured
with warmed 3T3 media from the fridge, the 3T3 media that had been warmed to 37 °C for 24
hours, and the sterile, powder-free latex glove eluted media warmed to 37 °C for 24 hours. The
well plates were then incubated for 24 and 48 hours.
2.2.9.3 Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and
imaged under the white-light microscope. The media was aspirated out of the well plates and the
micro-dish was subjected to methanol for 20 minutes to serve as a positive control for the staining
protocol. All wells were rinsed with DPBS, and the live/dead stock stain solution was made with
20 mL DPBS + 24 uL EthD-1 + 6 uL calcein AM. Next, 1.5 mL of the stain solution was placed
into each well for 5-10 minutes and aspirated out carefully as to not aspirate the cells. The wells
were then imaged using the widefield fluorescence microscope. This staining and imaging
procedure was repeated for the 48-hour timepoint wells with a replacement of the eluted media at
24 hours.
2.2.9.4 Trial #8 Results
Results from Trial #8 illustrated no cytotoxic effects from the negative control of 3T3
media warmed to 37 °C for 24 hours. This reinforced an extraction condition that was not
detrimental to the cells. The media eluted with a 6 and 15 cm2 sterile, powder-free latex sample
also demonstrated no cytotoxic effects. The 30 cm2 sample eluted media showed mild cytotoxic
effects, but it was not until the 45 cm2 sample eluted media that severe cytotoxic effects were seen.
These results suggested that the threshold of where cell death becomes evident happens with an
extraction ratio of ~45 cm2 sample size in 10 mL of media, at least for latex gloves. White-light
images are found in Appendix H and Figure 35. Results are summarized in Table 12.
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Table 12. Results of Trial #8 elution procedure. Numbers separated by commas represent
different fields of view.
Timepoint

Controls – all warmed to 37
°C for 24 hours

Cytotoxicity Scale

Interpretation

3T3 media

0, 0

Noncytotoxic

6 cm2 latex

0, 0

Noncytotoxic

15 cm2 latex

0, 0

Noncytotoxic

30 cm2 latex

1, 1

Mildly cytotoxic

45 cm2 latex

3, 3

Severely cytotoxic

60 cm2 latex

3, 3

Severely cytotoxic

3T3 media

0, 0

Noncytotoxic

6 cm2 latex

0, 0

Noncytotoxic

15 cm2 latex

0, 0

Noncytotoxic

30 cm2 latex

1, 1

Mildly cytotoxic

45 cm2 latex

3, 3

Severely cytotoxic

60 cm2 latex

3, 3

Severely cytotoxic

24-hour

48-hour

Controls

24 hours

48 hours

Effective Negative
Control – warmed
3T3 media from the
fridge

Effective Negative
Control – 3T3 media
warmed to 37 °C for
24 hours

77

Failed Positive
Control – 6cm2 Latex

Failed Positive
Control – 15cm2
Latex

Partially Failed
Positive Control –
30cm2 Latex

Effective Positive
Control – 45cm2
Latex

Effective Positive
Control – 60cm2
Latex

Figure 35. Trial #8 white-light images of 24- and 48- timepoint elution procedure, 10X.
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Widefield fluorescence images showed no cell presence with the 45 and 60 cm2 latex
sample eluted media. This occurred because most of the cells died, lifted off the bottom of the flask,
and were then aspirated during the staining process. These results are seen in Figures 36 and 37.
Calcein AM

Ethidium Homodimer-1

Effective
Negative
Control – 3T3
media

Effective
Negative
Control – 3T3
media at 37 °C
for 24 hours

Failed Positive
Control – 6 cm2
latex glove
eluted media at
37 °C for 24
hours

Failed Positive
Control – 15
cm2 latex glove
eluted media at
37 °C for 24
hours
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Partially Failed
Positive Control
– 30 cm2 latex
glove eluted
media at 37 °C
for 24 hours

Effective
Positive Control
– 45 cm2 latex
glove eluted
media at 37 °C
for 24 hours

Effective
Positive Control
– 60 cm2 latex
glove eluted
media at 37 °C
for 24 hours

Figure 36. Trial #8 widefield fluorescence images of 24-hour timepoint elution procedure.
10X magnification, 50% power, 500 ms exposure time.
Calcein AM

Ethidium Homodimer-1

Effective
Negtive Control
– 3T3 media
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Effective
Negative
Control – 3T3
media at 37 °C
for 24 hours

Failed Positive
Control – 6 cm2
latex glove
eluted media at
37 °C for 24
hours

Failed Positive
Control – 15 cm2
latex glove
eluted media at
37 °C for 24
hours

Partially Failed
Positive Control
– 30 cm2 latex
glove eluted
media at 37 °C
for 24 hours
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Effective
Positive Control
– 45 cm2 latex
glove eluted
media at 37 °C
for 24 hours

Effective
Positive Control
– 60 cm2 latex
glove eluted
media at 37 °C
for 24 hours

Figure 37. Trial #8 widefield fluorescence images of 48-hour timepoint elution procedure.
10X magnification, 50% power, 500 ms exposure time.
2.2.9.5 Trial #8 Issues Noted
No issues were noted with Trial #8.
2.2.9.6 Trial #8 Next Steps to Try
Since no issues were found with Trial #8, the next step was to utilize the final, optimized
protocols to test the cytotoxicity of polymers used in the BVM lab—ePTFE, PLGA, PLGA with
salt, PLLA, and PCL.
2.3

Discussion and Conclusion
In developing the necessary protocols for in vitro cytotoxicity testing of polymers used in

the fabrication of BVMs, it became evident after each trial run that some components of the
protocol would be kept, and some needed changing. A summary of each trial is outlined in Table
13.
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Table 13. Summary of trials.
Trial #

What was done

What was kept

What needed to be
changed
- Staining protocol /
positive control

Trial #1

Cytotoxicity protocols on
PLGA, PLGA with salt, and
PLLA – direct contact and
elution procedures.

- 6-well plates and
micro-dishes

- Media replacement
at 24 hours

- Elution extraction
conditions

- Cell seeding density

- Sterilization method

- Volume of water in
elution beaker / tinfoil
- Newly spun
polymers

Trial #2

Trial #3

Trial #4

- Cell seeding density

Cytotoxicity protocols on
ePTFE with cell viability assay
of calcein AM and ethidium
homodimer-1 – direct contact
and elution procedures.

- Staining protocol
- Direct contact
procedure

- Sterilization method
- Imaging protocol

- EtOH soak and
DPBS rinse
sterilization

Cytotoxicity protocols on
ePTFE including other
sterilization methods – elution
procedure.
Cytotoxicity protocols on
PLGA, PLGA with salt, PLLA,
and PCL – elution procedure.

- Stain positive
control

- Imaging protocol
- Elution positive
control
- Cell seeding density

- Cell seeding density
- Elution positive
control

- Elution extraction
conditions

- Sterilization method
Trial #5

Cytotoxicity protocols on
controls – elution procedure.

- Positive and
negative controls

- Elution extraction
conditions

Trial #6

Cytotoxicity protocols on
controls with different
extraction conditions – elution
procedure.

- New elution
extraction conditions

- Staining protocol

Trial #7

Stain screen.

- Staining protocol

N/A

Trial #8

Cytotoxicity protocols on
controls with different
extraction ratios – elution
procedure.

- Elution extraction
ratios

N/A

83

Overall, the trial iterations described above introduced several challenges that necessitated
addressing. The first limitation included troubleshooting of the staining and imaging protocol. It
was quickly determined that BBI and Trypan Blue would not be the proper stains for this specific
application and, therefore, calcein AM and ethidium homodimer-1 became the desirable assay.
Although this live/dead assay effectively differentiated between live and dead cells, the staining
protocol took several trials to optimize. Along with this, the proper cell seeding density became a
challenge early on as over-confluency of the cells was regularly observed. This was a problem
because over-confluency can lead to cell death, which could lead to false conclusions regarding
scaffold material cytotoxicity.
Another challenge included the controls. First, determining the appropriate positive and
negative controls for the direct contact and elution procedure proved challenging. The elution
controls displayed notable cell death with the extraction condition of 50 °C for 72 hours. This high
temperature for a long timepoint may have compromised components of the cell culture medium
and therefore caused detrimental effects to the cultured cells. The 3T3 culture media is made of
many different amino acids and vitamins, along with fetal bovine serum (FBS), penicillinstreptomycin, and fungizone. Cell culture media is usually stored in the fridge (2 – 8 °C) or the
water bath/incubator (37 °C). Subjecting this media to the high temperature of 50 °C for 72 hours
may have led to the denaturing of proteins within the media. Studies have shown that temperature
shifts are one of the main causes of precipitation (of proteins or other media components) in cell
culture. Precipitates can be harmful to cell viability due to their potential alteration of media
composition by removing nutrients and other desirable components [71]. Additionally, heat
treatment of FBS at 56 °C for longer than 30 minutes has proven to adversely affect cell health and
the heating of serum products can result in the formation of precipitates [72]. This trial finding was
what led to the incorporation of ISO 10993 cytotoxicity testing recommendations that alleviated
the issues found with the controls and elution-based methods.
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Another challenge came from the variability of the scaffold material samples. Throughout
these trial iterations, the electrospinner was unable to produce consistent polymer scaffolds via
mandrel spins. Fortunately, it became evident that the electrospinner was able to produce more
consistent flat sheet sample spins. Therefore, it was decided that the cytotoxicity testing would be
done on a combination of flat sheet samples and mandrel spins (i.e., whatever the electrospinner
could produce at that time). This was the reason for the seemingly random selection of
polymer/material types throughout the eight trials.
The final working protocol for cytotoxicity testing included direct contact and elutionbased methods. The direct contact procedure involved initial cell seeding, followed by sterilization
of the scaffold materials and the implementation of a proper positive control (samples left in EtOH
and unrinsed) and negative control (warmed 3T3 media from the fridge). Once sterilized, 3T3 cells
were directly exposed to the test and control articles and microscopically evaluated at 12-, 24-, and
48-hour timepoints. The elution procedure involved initial cell seeding, followed by sterilization
of the scaffold materials and implementation of positive controls (powder-free latex glove and
methanol subjection) and negative controls (3T3 media subjected to extraction conditions and
warmed 3T3 media from the fridge). Extracts were obtained by placing the test and control
materials in conicals of 3T3 media at 37 °C for 24 hours. The 3T3 cells were then cultured with
each fluid extract for 24- and 48-hour timepoints and microscopically examined for visible signs
of toxicity in response to the test and control materials. This final working protocol was
implemented in Chapters 3 and 4 to evaluate the biocompatibility of existing and novel BVM
scaffold polymers: ePTFE, PLGA, PLGA with salt, PLLA, and PCL.
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CHAPTER 3. AIM 2: BIOCOMPATIBILITY OF EXISTING BVM SCAFFOLD
POLYMERS: EPTFE AND PLGA
3.1

Introduction
The second aim of this thesis was to utilize the cytotoxicity protocols developed in Aim 1

to evaluate the biocompatibility of currently used polymers in the BVM lab: ePTFE and PLGA.
This study was important because it served as an additional confirmation of functional protocols—
since ePTFE and PLGA have been historically relevant scaffold materials in the fabrication of
BVMs. While ePTFE and PLGA are standard polymers used in BVM fabrication, they have also
been extensively studied for their biocompatibility in the field. Both polymers are well-established
with notable biocompatibility and low toxicity to cells. For example, in a post-market approval
(PMA) for Gore’s ePTFE Viabahn Endoprosthesis Implant, cytotoxicity elution tests demonstrated
noncytotoxic results from the device material on cells [73]. Additionally, in a different study,
cytotoxicity assays done on pure PLGA composite scaffolds were noncytotoxic to cells [74]. To
accomplish this aim, several studies involving direct contact and elution-based methods were
performed.
3.2

Methods and Results

3.2.1 Cell Seeding Procedure
Direct Contact Cell Seeding
Cells were seeded according to the Cell Seeding SOP in Appendix K. Passage 28 3T3 cells
at ~90% confluence in 1 T225 cell culture flask were harvested and resuspended in 24 mL of 3T3
media. Two mL of 3T3 media was placed into each well of two 6-well plates. Additionally, 0.3 mL
of the cell solution was placed into each well, resulting in a final cell seeding density of ~112,500
cells per well or ~11,800 cells/cm2. The 6-well plates were then placed in the incubator for 24 hours
at 37 °C and 5% CO2.
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Elution Cell Seeding
Cells were seeded according to the Cell Seeding SOP in Appendix K. Passage 33 3T3 cells
at ~90% confluence in 1 T225 cell culture flask were harvested and resuspended in 24 mL of 3T3
media. Two mL of 3T3 media was placed into each well of four 6-well plates and two micro-dishes.
Additionally, 0.3 mL of the cell solution was placed into each well of the 6-well plates and microdishes, resulting in a cell seeding density of ~112,500 cells per well or ~11,800 cells/cm2. The 6well plates and micro-dishes were then placed in the incubator for 24 hours.
3.2.2

Direct Contact Procedure
To begin the direct contact procedure with ePTFE and PLGA, an ePTFE tubular scaffold

(Fig. 38) and an electrospun, PLGA flat sheet sample (Fig. 39) were cut into sections (~6 cm2). The
direct contact SOP in Appendix L was then followed. The samples were sterilized in sterile 70%
EtOH for 20 minutes. After 20 minutes, the conicals were replaced with DPBS and shaken for 1
minute to rid the polymers of any residual EtOH. One sample of PLGA and ePTFE were each left
in EtOH to serve as positive controls. Using sterile forceps, the samples were transferred into
corresponding wells and well plates were placed in the incubator until imaging. The well plates
were evaluated and imaged under the white-light microscope at 12-, 24-, and 48-hour timepoints.

Figure 38. ePTFE tubular scaffold sample.
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Figure 39. Electrospun PLGA flat sheet sample. A) PLGA sample 15 wt.% PLGA/CHCL3 on
C

A

flat sheet collector, B) the same PLGA sample removed from the collector.

3.2.3

Elution Procedure
To begin the elution procedure (Appendix M), six conicals were prepared, each with 10

mL of 3T3 media. The negative control was 3T3 media with no sample. The positive control was
prepared by placing a 45 cm2 sterile, powder-free latex glove sample in media. The polymer
samples tested included an ePTFE tubular scaffold (~10 cm2), a PLGA tubular scaffold (~7 cm2),
and a PLGA flat sheet sample (~45 cm2). Samples were placed in conicals that were warmed to
37°C in the incubator for 24 hours. After 24 hours, the samples were removed from the conicals,
leaving only the eluted media. The 3T3 cells were cultured with warmed 3T3 media from the fridge
(negative control), 3T3 media warmed to 37 °C for 24 hours (negative control), media eluted with
a sample of sterile, powder-free latex glove and warmed to 37 °C for 24 hours (positive control),
as well as the medias eluted with the ePTFE tubular scaffold, PLGA tubular scaffold, and PLGA
flat sheet. The well plates containing the cultured cells were then incubated for 24 and 48 hours.
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3.2.4

Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and

imaged under the white-light microscope. The media was aspirated out of the well plates and the
micro-dish was subjected to methanol for 20 minutes to serve as a positive control for the staining
protocol (Appendix N). All wells were rinsed with DPBS and 1.5 mL of a live/dead stock stain
solution of 20 mL DPBS + 24 uL EthD-1 + 6 uL calcein AM was placed into each well for 5-10
minutes. After 5-10 minutes, the stain solution was aspirated out carefully as to not aspirate the
cells. Each well was imaged using the widefield fluorescence microscope (Appendix O). This
staining and imaging procedure was repeated for the 48-hour timepoint wells with a replacement
of the eluted media at 24 hours.
3.2.5 Cell Counting Procedure
A cell counting procedure was implemented in Aim 2 to provide a quantitative
representation of scaffold material biocompatibility. Images taken with the widefield fluorescence
microscope were opened in ImageJ for proper cell counting (Appendix P). Each image was
converted to 16-bit and the threshold was adjusted to ensure each nuclei was individually counted.
Each particle was then analyzed in pixel2 units. Live cells were counted based on the calcein AM
stained images and dead cells were counted based on the ethidium homodimer-1 stained images.
The results were tabulated as the number of live cells, the number of dead cells, and the ratio of
live to dead cells for the positive controls, negative controls, ePTFE, and PLGA.
3.2.6

Results

Direct Contact Results
Results from this direct contact study illustrated that ePTFE and PLGA (solvent:
chloroform) were noncytotoxic to 3T3 cells. White-light images from the ePTFE and PLGA direct
contact procedure can be found in Appendix I. These results are summarized in Table 14.
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Table 14. Results of ePTFE and PLGA direct contact procedure. Numbers separated by
commas represent different fields of view.
Timepoint

12-hour

24-hour

48-hour

Sample

Cytotoxicity Scale

Interpretation

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA

0, 0

Noncytotoxic

PLGA in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA

0, 0

Noncytotoxic

PLGA in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

ePTFE

0, 0

Noncytotoxic

ePTFE in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA

0, 0

Mildly cytotoxic

PLGA in EtOH (pos. control)

3, 3

Severely cytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

Elution Results
Results from the elution procedure illustrated that ePTFE and PLGA were noncytotoxic at
24 hours. Negative controls displayed highly confluent, live cells and almost no dead cells. Positive
controls displayed high cell death and cell detachment from the surface of the flask. At 48 hours,
results illustrated that ePTFE and PLGA were noncytotoxic as well. At this timepoint, negative
controls continued to display highly confluent, live cells and almost no dead cells. Positive controls
displayed further cell detachment from the surface of the flask and even greater cell death. Whitelight images from the ePTFE and PLGA elution procedure can be found in Appendix I. These
results are summarized in Table 15.
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Table 15. Results of ePTFE and PLGA elution procedure. Numbers separated by commas
represent different fields of view.
Timepoint

24-hour

48-hour

Sample

Cytotoxicity Scale

Interpretation

3T3 media (neg. control)

0, 0

Noncytotoxic

3T3 media warmed to 37 °C
for 24 hours (neg. control)

0, 0

Noncytotoxic

45 cm2 latex (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

ePTFE tubular scaffold

0, 0

Noncytotoxic

PLGA tubular scaffold

0, 0

Noncytotoxic

PLGA flat sheet

0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

3T3 media warmed to 37 °C
for 24 hours (neg. control)

0, 0

Noncytotoxic

45 cm2 latex (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

ePTFE tubular scaffold

0, 0

Noncytotoxic

PLGA tubular scaffold

0, 0

Noncytotoxic

PLGA flat sheet

0, 0

Noncytotoxic

At 24 hours, the positive control of powder-free latex glove eluted media was effective in
killing the cells. This was confirmed by the absence of cells in the positive control stained and
imaged wells and was due to cell detachment and aspiration during the staining procedure. The
other positive control of methanol for 20 minutes was effective in killing the cells and
demonstrating the efficacy of the stain. This was confirmed by the intense fluorescence of ethidium
homodimer-1 in the stained and imaged well. At 24 hours, the PLGA tubular scaffold, PLGA flat
sheet, and ePTFE tubular scaffold eluted media illustrated a high confluency of live cells and no
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dead cells (Fig. 40). Images at 48 hours illustrated similar results, but with an even greater
confluency of live cells (Fig. 41).
Calcein AM

Ethidium Homodimer-1

Effective
Negative
Control – 3T3
media

Effective
Negative
Control – 3T3
media at
37°C for 24
hours

Effective
Positive
Control – 45
cm2 latex
glove eluted
media at
37°C for 24
hours

Effective
Positive
Control –
subjection to
methanol for
20 minutes
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PLGA
tubular
scaffold
eluted media
at 37°C for
24 hours

PLGA flat
sheet eluted
media at
37°C for 24
hours

ePTFE
tubular
scaffold
eluted media
at 37°C for
24 hours

Figure 40. PLGA and ePTFE widefield fluorescence images of 24-hour timepoint elution
procedure. 10X magnification, 50% power, 500 ms exposure time.

Calcein AM

Ethidium Homodimer-1

Effective
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Control – 3T3
media
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37°C for 24
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Effective
Positive
Control –
subjection to
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20 minutes

PLGA tubular
scaffold
eluted media
at 37°C for
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PLGA flat
sheet eluted
media at
37°C for 24
hours

ePTFE
tubular
scaffold
eluted media
at 37°C for
24 hours

Figure 41. PLGA and ePTFE widefield fluorescence images of 48-hour timepoint elution
procedure. 10X magnification, 50% power, 500 ms exposure time.

At 24 hours, the negative controls of warmed 3T3 media from the fridge and 3T3 media
incubated at 37 °C for 24 hours resulted in high cell viability (923 live cells and 1175 live cells,
respectively) and minimal cell death (1 dead cell and 0 dead cells, respectively). At 48 hours, these
negative controls continued to illustrate high cell viability (1056 live cells and 1017 live cells,
respectively) and minimal cell death (4 dead cells and 0 dead cells, respectively). At 24 and 48
hours, the powder-free latex glove eluted media resulted in no live or dead cells due to cell
aspiration during the staining protocol. At 24 and 48 hours, the subjection of methanol for 20
minutes resulted in no live cells and high cell death (1290 dead cells at 24 hours and 1641 dead
cells at 48 hours). At 24 hours, the PLGA tubular scaffold, PLGA flat sheet, and ePTFE tubular
scaffold eluted media also resulted in high cell viability (1051 live cells, 966 live cells, and 945
live cells, respectively) and minimal cell death (0 dead cells, 1 dead cell, and 0 dead cells,
respectively). At 48 hours, these polymers continued to illustrate high cell viability (1013 live cells,
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1003 live cells, and 1125 live cells, respectively) and minimal cell death (3 dead cells, 1 dead cell,
and 1 dead cell, respectively). These results are summarized in Table 16.
Table 16. Results of ePTFE and PLGA elution procedure cell counts.
Timepoint

24-hour

48-hour

Sample

# of Live
Cells

# of Dead
Cells

Ratio of
Live/Dead

3T3 media (neg. control)

923

1

923/1

3T3 media warmed to 37
°C for 24 hours (neg.
control)

1175

0

1175/0

Latex (pos. control)

0

0

0/0

Methanol (pos. control)

0

1290

0/1290

PLGA tubular scaffold

1051

0

1051/0

PLGA flat sheet

966

1

966/1

ePTFE tubular scaffold

945

0

945/0

3T3 media (neg. control)

1056

4

1056/4

3T3 media warmed to 37
°C for 24 hours (neg.
control)

1017

0

1017/0

Latex (pos. control)

0

0

0/0

Methanol (pos. control)

0

1641

0/1641

PLGA tubular scaffold

1013

3

1013/3

PLGA flat sheet

1003

1

1003/1

ePTFE tubular scaffold

1125

1

1125/1

Results from this elution study confirm that ePTFE and PLGA (solvent: chloroform) were
noncytotoxic to 3T3 cells.
3.3

Discussion and Conclusion
The second aim of this thesis involved cytotoxicity testing of standard BVM polymers used

in the tissue engineering lab—ePTFE and PLGA—through direct contact and elution-based
methods. The direct contact method involved placing the scaffold materials directly onto 3T3 cells
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and evaluating the cells at 12-, 24-, and 48-hour timepoints for signs of toxicity. Results from the
direct contact procedure illustrated that ePTFE and PLGA were noncytotoxic at 12-, 24-, and 48hour timepoints (Table 17). The elution method involved incubating ePTFE, PLGA, and control
materials in 3T3 media at 37 °C for 24 hours and culturing 3T3 cells with the fluid extracts. The
cells were then observed for signs of toxicity at 24- and 48-hour timepoints. Results from the elution
procedure illustrated that ePTFE and PLGA were noncytotoxic to 3T3 cells (Table 17).
Table 17. Results from cytotoxicity testing on ePTFE and PLGA.
Scaffold Material

Elution Procedure

Direct Contact Procedure

ePTFE

Noncytotoxic

Noncytotoxic

PLGA (solvent: chloroform)

Noncytotoxic

Noncytotoxic

Challenges and limitations from this aim included the inability of the electrospinner to
produce mandrel spins (aka “tubular scaffolds”) effectively and consistently. Thus, the cytotoxicity
testing was done on a PLGA flat sheet sample instead of the lab’s standard scaffold spins. Ideally,
to better model the standard BVM characteristics, cytotoxicity testing in the tissue engineering lab
would be performed with higher quality and adequately-sized tubular scaffolds. This would ensure
more representative biocompatibility results.
The results from this study were consistent with results from cytotoxicity testing done in
previously published ePTFE and PLGA studies. As mentioned in Section 3.1, ePTFE and PLGA
are well-established polymers with notable biocompatibility and low toxicity to cells. Therefore,
this study provided a baseline for the comparison of new BVM materials, including PLGA with
salt, PLLA, and PCL, which was Aim 3 and is described in Chapter 4.
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CHAPTER 4. AIM 3: BIOCOMPATIBILITY OF NOVEL BVM SCAFFOLD POLYMERS:
PLGA WITH SALT, PLLA, AND PCL
4.1

Introduction
The third aim of this thesis was to utilize the cytotoxicity protocols developed in Aim 1 to

evaluate the biocompatibility of novel polymers in the BVM lab: PLGA with salt, PLLA, and PCL.
This study was important because biocompatibility of the newer polymers had yet to be fully
characterized. As described in Section 3.1, PLGA is well-established with well-known
biocompatibility, but adding BTEAC salt into the scaffold could have significant impacts on
biocompatibility. PLLA and PCL are also well-known biocompatible polymers. For example,
cytotoxicity testing performed on an electrospun PLLA fiber membrane demonstrated noncytotoxic
effects on cells [75]. Additionally, in a different study, cytotoxicity testing done on a PCL
nanofibrous scaffold was noncytotoxic to cells [76]. However, because these polymers are
dissolved in solvents—chloroform and dichloromethane—cytotoxicity testing was still necessary.
To accomplish this aim, several studies involving direct contact and elution-based methods were
performed.
4.2

Methods and Results

4.2.1

Cell Seeding Procedure

Direct Contact Cell Seeding
Cells were seeded according to the Cell Seeding SOP in Appendix K. Passage 28 3T3 cells
at ~90% confluence in 1 T225 cell culture flask were harvested and resuspended in 24 mL of 3T3
media. Two mL of 3T3 media was placed into each well of three 6-well plates. Next, 0.3 mL of the
cell solution was placed into each well, resulting in a final cell seeding density of ~112,500 cells
per well or ~11,600 cells/cm2. The 6-well plate was then placed in the incubator for 24 hours at 37
°C and 5% CO2.
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Elution Cell Seeding
Cells were seeded according to the Cell Seeding SOP in Appendix K. Passage 34 3T3 cells
at ~90% confluence in 1 T225 cell culture flask were harvested and resuspended in 24 mL of 3T3
media. Two mL of 3T3 media was placed into each well of six 6-well plates and two micro-dishes.
Next, 0.3 mL of the cell solution was placed into each well of the 6-well plates and micro-dishes,
resulting in a cell seeding density of ~112,500 cells per well or ~11,600 cells/cm2. The 6-well plates
and micro-dishes were then placed in the incubator for 24 hours.
4.2.2

Direct Contact Procedure
To begin the direct contact procedure, samples of PLGA with salt, PLLA, and PCL (Fig.

42-44) were cut into sections (~6 cm2). The direct contact SOP in Appendix L was then followed.
The samples were sterilized in sterile 70% EtOH for 20 minutes. The conicals were replaced with
DPBS and shaken for 1 minute to rid the polymers of any residual EtOH. A sample of each polymer
was left in EtOH to serve as a positive control.

Figure 42. PCL samples. A) 12.5% PCL flat sheet spun on 210310, B) 12.5% PCL flat sheet
spun on 210215, and C) PCL scaffold.
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Figure 43. PLLA sample. A) PLLA sample on the flat sheet collector, B) the same PLLA
sample removed from the collector.

Figure 44. PLGA with 1.5 wt.% BTEAC salt sample.
Using sterile forceps, the samples were transferred into the well plates, which were
promptly placed into the incubator until imaging (Fig. 45). The well plates were evaluated and
imaged under the white-light microscope at 12-, 24-, and 48-hour timepoints.

Figure 45. Sterilized polymer samples placed onto the cells in the direct contact procedure.
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4.2.3

Elution Procedure
To begin the elution procedure (Appendix M), eight conicals were prepared, each with 10

mL of 3T3 media. The negative control consisted of warmed 3T3 media from the fridge with no
sample. The positive control was prepared by placing a 45 cm2 sterile, powder-free latex glove
sample in media. The polymer samples tested, and their corresponding surface areas, are outlined
in Table 18.
Table 18. Aim 3 elution test materials and corresponding surface areas.
Sample

Total Surface Area (cm2)

PLGA with salt tubular scaffold

~ 15

PLGA with salt flat sheet

~ 45

PLLA tubular scaffold (x2)

~ 25

PLLA flat sheet

~ 25

PCL tubular scaffold (x2)

~ 20

PCL flat sheet

~ 30

Samples were placed in conicals and warmed to 37 °C for 24 hours in the incubator. After
24 hours, the samples were removed, leaving only the eluted media left. The 3T3 cells were cultured
with warmed 3T3 media from the fridge (negative control), 3T3 media warmed to 37 °C for 24
hours (negative control), media that was eluted with a sample of sterile, powder-free latex glove
and warmed to 37 °C for 24 hours (positive control), as well as the medias eluted with the PLGA
with salt, PLLA, and PCL samples. The well plates containing the cultured cells were then
incubated for 24 and 48 hours.
4.2.4

Staining and Imaging Procedure
After 24 hours of incubation with the eluted media, the well plates were evaluated and

imaged under the white-light microscope. Media was aspirated out of the well plates and the microdish was subjected to methanol for 20 minutes to serve as a positive control for the staining protocol
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(Appendix N). All wells were rinsed with DPBS and 1.5 mL of a live/dead stock stain solution of
30 mL of DPBS + 24 uL Ethd-1 + 6 uL calcein AM was placed into each well for 5-10 minutes.
After 5-10 minutes, the stain solution was aspirated out of each well carefully as to not aspirate the
cells. Each well was then imaged using the widefield fluorescence microscope (Appendix O). This
staining and imaging procedure was repeated for the 48-hour timepoint wells with a replacement
of the eluted media at 24 hours.
4.2.5

Cell Counting Procedure
Similar to Aim 2, a cell counting procedure was implemented in these studies to provide a

quantitative representation of scaffold material biocompatibility. Images taken with the widefield
fluorescence microscope were opened in ImageJ for proper cell counting (Appendix P). Each image
was converted to 16-bit and the threshold was adjusted to ensure each nuclei was individually
counted. Each particle was then analyzed in pixel2 units. Live cells were counted based on the
calcein AM stained images and dead cells were counted based on the ethidium homodimer-1
stained images. The results were tabulated as the number of live cells, the number of dead cells,
and the ratio of live to dead cells for the positive controls, negative controls, PLLA, PLGA with
salt, and PCL.
4.2.6

Results

Direct Contact Results
Results from this study illustrated no cytotoxic effects from PLLA, PLGA with salt, and
PCL at 12 hours. At 24 hours, PLGA with salt and PCL began to display mild cytotoxic effects
while PLLA displayed noncytotoxic effects. At 48 hours, PLGA with salt and PCL continued to
exhibit mild cytotoxic effects. These mild cytotoxic effects included low confluence and limited
cell growth seen in several areas of the well. The PLLA direct contact at 48 hours showed
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noncytotoxic effects. White-light images from the direct contact procedure can be found in
Appendix J. These results are summarized in Table 19.
Table 19. Results of PLLA, PLGA with salt, and PCL direct contact procedure. Numbers
separated by commas represent different fields of view.
Timepoint

12-hour

24-hour

48-hour

Polymer type

Cytotoxicity
Scale

Interpretation

PLLA

0, 0

Noncytotoxic

PLLA in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA w/ salt

0, 0

Noncytotoxic

PLGA w/ salt in EtOH (pos. control)

3, 3

Severely cytotoxic

PCL tubular scaffold

0, 0

Noncytotoxic

PCL flat sheet 210310

0, 0

Noncytotoxic

PCL flat sheet 210215

0, 0

Noncytotoxic

PCL in EtOH (pos. control)

3, 3

Severely cytotoxic

PLLA

0, 0

Noncytotoxic

PLLA in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA w/ salt

0, 2

Mildly cytotoxic

PLGA w/ salt in EtOH (pos. control)

3, 3

Severely cytotoxic

PCL tubular scaffold

2, 0

Mildly cytotoxic

PCL flat sheet 210310

0, 2

Mildly cytotoxic

PCL flat sheet 210215

0, 0

Noncytotoxic

PCL in EtOH (pos. control)

3, 3

Severely cytotoxic

PLLA

0, 0

Noncytotoxic

PLLA in EtOH (pos. control)

3, 3

Severely cytotoxic

PLGA w/ salt

0, 2

Mildly cytotoxic

PLGA w/ salt in EtOH (pos. control)

3, 3

Severely cytotoxic

PCL tubular scaffold

0, 2

Mildly cytotoxic

PCL flat sheet 210310

1, 0

Mildly cytotoxic

PCL flat sheet 210215

0, 1

Mildly cytotoxic

PCL in EtOH (pos. control)

3, 3

Severely cytotoxic
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Elution Results
Results from the elution procedure illustrated that PLGA with salt, PLLA, and PCL were
noncytotoxic at 24 hours. Negative controls displayed highly confluent, live cells and almost no
dead cells. Positive controls displayed cell detachment from the surface of the flask and high cell
death. At 48 hours, results illustrated that PLGA with salt, PLLA, and PCL were noncytotoxic as
well. At this timepoint, negative controls continued to display highly confluent, live cells and
almost no dead cells. Positive controls displayed further cell detachment from the surface of the
flask and even greater cell death. White-light images from the PLGA with salt, PLLA, and PCL
elution procedure can be found in Appendix J. These results are summarized in Table 20.
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Table 20. Results of PLLA, PLGA with salt, and PCL elution procedure. Numbers separated
by commas represent different fields of view.
Timepoint

24-hour

48-hour

Sample

Cytotoxicity
Scale

Interpretation

3T3 media (neg. control)

0, 0

Noncytotoxic

3T3 media at 37 °C for 24 hours (neg.
control)

0, 0

Noncytotoxic

Latex (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

PLGA w/ salt tubular scaffold

0, 0

Noncytotoxic

PLGA w/ salt flat sheet

0, 0

Noncytotoxic

PLLA tubular scaffold

0, 0

Noncytotoxic

PLLA flat sheet

0, 0

Noncytotoxic

PCL tubular scaffold

0, 0

Noncytotoxic

PCL flat sheet

0, 0

Noncytotoxic

3T3 media (neg. control)

0, 0

Noncytotoxic

3T3 media at 37 °C for 24 hours (neg.
control)

0, 0

Noncytotoxic

Latex (pos. control)

3, 3

Severely cytotoxic

Methanol (pos. control)

3, 3

Severely cytotoxic

PLGA w/ salt tubular scaffold

0, 0

Noncytotoxic

PLGA w/ salt flat sheet

0, 0

Noncytotoxic

PLLA tubular scaffold

0, 0

Noncytotoxic

PLLA flat sheet

0, 0

Noncytotoxic

PCL tubular scaffold

0, 0

Noncytotoxic

PCL flat sheet

0, 0

Noncytotoxic

At 24 hours, the positive control of powder-free latex glove eluted media was effective in
killing the cells. This was confirmed by the absence of cells in the positive control stained and
imaged wells and was due to cell detachment and aspiration during the staining procedure. The
other positive control of methanol for 20 minutes was effective in killing the cells and
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demonstrating the efficacy of the stain. This was confirmed by the intense fluorescence of ethidium
homodimer-1 in the stained and imaged well. At 24 hours, the PLGA with salt tubular scaffold and
flat sheet, the PLLA tubular scaffold and flat sheet, and the PCL tubular scaffold and flat sheet
eluted media illustrated a high confluency of live cells and almost no dead cells (Fig. 46). Images
at 48 hours illustrated similar results, but with an even greater confluency of live cells (Fig. 47).
Calcein AM

Ethidium Homodimer-1

Effective
Negative
Control – 3T3
media

Effective
Negative
Control – 3T3
media at 37 °C
for 24 hours

Effective
Positive
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45cm2 latex
glove eluted
media at 37 °C
for 24 hours
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Effective
Positive
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PLLA tubular
scaffold eluted
media at 37 °C
for 24 hours

PLLA flat
sheet eluted
media at 37 °C
for 24 hours

PLGA with
salt tubular
scaffold eluted
media at 37 °C
for 24 hours
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PLGA with
salt flat sheet
eluted media
at 37 °C for 24
hours

PCL tubular
scaffold eluted
media at 37 °C
for 24 hours

PCL flat sheet
eluted media
at 37 °C for 24
hours

Figure 46. PLLA, PLGA with salt, and PCL widefield fluorescence images of 24-hour
timepoint elution procedure. 10X magnification, 50% power, 500 ms exposure time.
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subjection
for 20
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tubular
scaffold
eluted media
at 37 °C for
24 hours
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PLLA flat
sheet eluted
media at
37°C for 24
hours

PLGA with
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eluted media
at 37 °C for
24 hours

PLGA with
salt flat sheet
eluted media
at 37 °C for
24 hours

PCL tubular
scaffold
eluted media
at 37 °C for
24 hours
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PCL flat
sheet eluted
media at
37°C for 24
hours

Figure 47. PLLA, PLGA with salt, and PCL widefield fluorescence images of 48-hour
timepoint elution procedure. 10X magnification, 50% power, 500 ms exposure time.

At 24 hours, the negative controls of warmed 3T3 media from the fridge and 3T3 media
incubated at 37 °C for 24 hours resulted in high cell viability (1286 live cells and 1244 live cells,
respectively) and minimal cell death (5 dead cells and 3 dead cells, respectively). At 48 hours, these
negative controls continued to illustrate high cell viability (2020 live cells and 1635 live cells,
respectively) and minimal cell death (0 dead cells and 2 dead cells, respectively). At 24 and 48
hours, the powder-free latex glove eluted media resulted in no live or dead cells due to cell
aspiration during the staining protocol. At 24 and 48 hours, the subjection of methanol for 20
minutes resulted in no live cells and high cell death (1624 dead cells at 24 hours and 1635 dead
cells at 48 hours). At 24 hours, the PLLA tubular scaffold and flat sheet, PLGA with salt tubular
scaffold and flat sheet, and PCL tubular scaffold and flat sheet eluted media also resulted in high
cell viability (1204 live cells, 1191 live cells, 982 live cells, 1293 live cells, 1174 live cells, and
1309 live cells, respectively) and minimal cell death (3 dead cells, 4 dead cells, 5 dead cells, 6 dead
cells, 6 dead cells, and 11 dead cells, respectively). At 48 hours, these polymers continued to
illustrate high cell viability (1740 live cells, 2287 live cells, 2287 live cells, 1264 live cells, 2142
live cells, and 1793 live cells, respectively) and minimal cell death (7 dead cells, 2 dead cells, 15
dead cells, 8 dead cells, 5 dead cells, 3 dead cells, respectively). These results are summarized in
Table 21.
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Table 21. Results of PLLA, PLGA with salt, and PCL elution procedure cell counts.
Timepoint

24-hour

48-hour

Sample

# of Live
Cells

# of Dead
Cells

Ratio of
Live/Dead

3T3 media (neg. control)

1286

5

1286/5

3T3 media warmed to 37
°C for 24 hours (neg.
control)

1244

3

1244/3

Latex (pos. control)

0

0

0

Methanol (pos. control)

0

1624

0/1624

PLLA scaffold

1204

3

1204/3

PLLA flat sheet

1191

4

1191/4

PLGA w/ salt scaffold

982

5

982/5

PLGA w/ salt flat sheet

1293

6

1293/6

PCL scaffold

1174

6

1174/6

PCL flat sheet

1309

11

1309/11

3T3 media (neg. control)

2020

0

2020/0

3T3 media warmed to 37
°C for 24 hours (neg.
control)

1635

2

1635/2

Latex (pos. control)

0

0

0

Methanol (pos. control)

0

1635

0/1635

PLLA scaffold

1740

7

1740/7

PLLA flat sheet

2287

2

2287/2

PLGA w/ salt scaffold

2287

15

2287/15

PLGA w/ salt flat sheet

1264

8

1264/8

PCL scaffold

2142

5

2142/5

PCL flat sheet

1793

3

1793/3

Results from this elution study demonstrated that PLGA with salt (solvent: chloroform),
PLLA (solvent: chloroform), and PCL (solvent: dichloromethane) were noncytotoxic to 3T3
cells.
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4.3

Discussion and Conclusion
The third aim of this thesis involved cytotoxicity testing of novel BVM polymers used in

the tissue engineering lab—PLGA with salt, PLLA, and PCL—through direct contact and elutionbased methods. The direct contact method involved placing the scaffold materials directly onto 3T3
cells and evaluating the cells at 12-, 24-, and 48-hour timepoints for signs of toxicity. Results from
the direct contact procedure illustrated that PLGA with salt, PLLA, and PCL were noncytotoxic at
12-hour timepoints. At 24- and 48-hour timepoints, PLGA with salt and PCL demonstrated mild
cytotoxic effects (Table 22). The elution method involved incubating PLGA with salt, PLLA, PCL,
and control materials in 3T3 media at 37 °C for 24 hours and culturing 3T3 cells with the fluid
extracts. The cells were then observed for signs of toxicity at 24- and 48-hour timepoints. Results
from the elution procedure illustrated that PLGA with salt, PLLA, and PCL were noncytotoxic to
3T3 cells (Table 22). The results from this elution study were consistent with results from
cytotoxicity testing done in previously published PLGA, PLLA, and PCL studies. As mentioned in
Section 4.1, PLGA, PLLA, and PCL are well-established polymers with notable biocompatibility
and low toxicity to cells. However, cytotoxicity testing was still valuable because these polymers
were dissolved in solvents (chloroform and dichloromethane), electrospun using protocols in our
lab, and had yet to be characterized for their biocompatibility.
Table 22. Results from cytotoxicity testing on PLGA with salt, PLLA, and PCL.
Scaffold Material

Direct Contact Procedure

Elution Procedure

PLGA with salt (solvent: chloroform)

Mildly cytotoxic

Noncytotoxic

PLLA (solvent: chloroform)

Noncytotoxic

Noncytotoxic

PCL (solvent: dichloromethane)

Mildly cytotoxic

Noncytotoxic

While the elution procedure of PLGA with salt and PCL illustrated they were noncytotoxic
to cells, the direct contact procedure showed mild cytotoxic effects from PLGA with salt and PCL
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at 24- and 48-hour timepoints. Potential causes for the mild cytotoxic effects along with the
observed variability between test methods are discussed below.
4.3.1 Discussion of Cytotoxic Variability
Potential causes of the mild cytotoxic effects observed with PLGA with salt and PCL in
the direct contact procedure could be linked to the addition of benzyl triethylammonium chloride
(BTEAC) salt to PLGA, or dichloromethane’s (DCM) use as a solvent for PCL. The addition of
BTEAC salt to PLGA presents a potential cytotoxicity concern. The PLGA dissolved in chloroform
did not result in cytotoxic effects from the elution or direct contact procedure, while PLGA with
salt illustrated mild cytotoxic effects from the direct contact procedure. This reinforced the potential
for cytotoxic effects of BTEAC salt. This salt has been shown in literature to cause serious irritation,
along with acute toxicity [77]. While no studies were found specifically on the cytotoxicity of
BTEAC salt on cells, future studies should be performed to determine if this addition of salt to
PLGA does in fact present a biocompatibility concern.
Additionally, PCL was the only polymer dissolved in DCM, a solvent shown to have
toxicological effects. In a study evaluating the cytotoxicity of a DCM extract on cells, it was
concluded that the extract had significant cytotoxic effects on cells within a concentration range of
0.1 to 100 ug/ml [78]. DCM is an organic solvent known to be highly toxic and exposure can result
in cough, pulmonary irritation, mucous membrane irritation, skin irritation, and corrosive burns
[79]. Due to its inherent toxicity, using DCM as a solvent in the electrospinning of PCL could be a
contributing factor to the mild cytotoxicity seen from PCL’s direct contact procedure.
Another potential cause of variability between the direct contact and elution results could
include insufficient extraction ratios in the elution test method. For example, the scaffold and flat
sheet samples of PCL were unable to reach the ~45 cm2 in 10 mL of 3T3 media that was determined
in Trial #8 to be the proper extraction ratio for powder-free latex gloves. Although this extraction
ratio may not be compatible with each scaffold material type, it was able to properly leach toxins
114

from the latex gloves. Insufficient extraction ratios were due to the inability to spin large enough
sample sizes. The PCL extraction ratio of ~30 cm2 in 10 mL of media may not have been able to
demonstrate signs of toxicity relative to the direct contact procedure that did present mild cytotoxic
effects. The inability to reach this proper extraction ratio could have led to false conclusions with
PCL from the elution procedure. For PLGA with salt, the flat sheet sample was able to reach the
elution procedure’s sufficient extraction ratio of ~45 cm2 in 10 mL of media and still demonstrated
variability between the elution and direct contact procedure cytotoxicity results. Therefore,
insufficient extraction ratios may not have been the primary cause of variability between the
cytotoxicity results. Future elution methods should consider that not all polymer types sufficiently
leach toxins with the same extraction ratio.
Both the addition of BTEAC salt to PLGA and the use of DCM as a solvent for PCL could
be the potential causes of observed mild cytotoxic effects. Alternatively, the elution procedure’s
potentially insufficient extraction ratio could be the cause of the differing cytotoxicity results
observed between the elution and direct contact procedure.
4.3.2 Discussion of Test Method Variability
As implied in the discussion above, if the salt and DCM were definitively problematic, it
would have been expected to see similar cytotoxicity results from the elution procedure. In addition
to elution sample size, there are several other potential causes of the variability between the elution
and direct contact test methods due to the methods themselves. First, the direct contact procedure
has limitations due to physical interaction of the test sample with the cell layer. A study evaluating
in vitro cytotoxicity of biomaterials illustrated that cell death and detachment was greatest in the
direct contact tests when compared to the indirect contact tests of a cytotoxic control [80].
Additional studies have proven that the direct contact procedure is not recommended for very low
or very high density material. Very low density material will tend to float in the cell growth media
and very high density material will tend to sit on top of the cells, potentially damaging the cells
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when placed [81]. According to ISO 10993-5, extreme care must be taken to prevent any
unnecessary movement of the scaffold materials when placed on the cell layer. For example, areas
of dislodged cells could be due to the unnecessary movement of the test samples [53]. While
extreme care was taken in all direct contact studies to ensure no unnecessary movement of the
samples on top of the cells, it is possible that disturbance of the cells could have occurred during
placement of the sample or during evaluation. For these reasons, in vitro testing using a test sample
extract (i.e., the elution procedure) is more frequently used in cytotoxicity testing due to a mitigated
potential risk of cellular trauma due to contact between the material and the cell layer [82].
Another potential cause for variability between the direct contact and elution-based
cytotoxicity test methods have been identified in past studies. Under the assumption that no
physical disruption of the cell layer occurs during placement of the sample, there is evidence that
direct contact methods can better detect cytotoxic effects when compared to indirect contact
methods. In a comparison between direct contact and elution-based methods done with
polydioctylfluorene (PFO), it was determined that cytotoxicity tests of extracts in the elution-based
methods were inadequate because PFO has been proven to cause blindness when in direct contact
with human tissue [83]. Therefore, the direct contact method was more effective than the elution
procedure. The UNE-ISO, the body legally responsible for the development of standards in Spain,
suggests that testing procedures should reflect the application in which the test sample will be used
[83]. In the case of our lab, our scaffold materials are coming in direct contact with cells and thus
the direct contact method may be a more representative cytotoxicity testing procedure. This same
study identified that the elution-based method was unable to detect cellular toxicity due to an
insufficient amount of leachable toxic components from the samples. The direct contact method
ensures that cells are exposed directly to the test subjects; therefore, providing more meaningful
data regarding the potential toxicity of the test subject [83].
In summary, variability between the direct contact and elution-based test methods could be
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due to the physical disruption of cells during the direct contact procedure or to the inherent nature
of the direct contact procedure which is more sensitive to cytotoxic effects. Prior to implementing
either cytotoxicity test method, it is important to consider the advantages and disadvantages of each
method. Since each provides valuable data, future studies should continue to implement both direct
contact and elution-based methods.
Challenges and limitations from this aim were consistent with studies performed in Aim 2,
including the inability of the electrospinner to produce mandrel spins (aka “tubular scaffolds”)
effectively and consistently. Thus, the cytotoxicity testing was done on a combination of flat sheet
samples and partial mandrel spins. As mentioned in Aim 2, to better model the standard BVM
characteristics, cytotoxicity testing in the tissue engineering lab would be ideally performed with
higher quality and adequately-sized tubular scaffolds. This would ensure more representative
biocompatibility results.
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CHAPTER 5. DISCUSSION AND CONCLUSION
5.1 Summary and Aims of the Thesis
Tissue-engineered blood vessel mimics (BVMs) are useful preclinical testing models for
vascular devices. Electrospun polymer scaffolds are the foundation of BVMs and, therefore, must
be adequately tested for biocompatibility before being seeded with human vascular cell types.
Because an assortment of polymer types are used in BVMs, general biocompatibility testing
methods are necessary to ensure safe interaction between each polymer material and human
vascular cells.
The overall goal of this thesis was to establish methods for evaluating the biocompatibility,
specifically the cytotoxicity, of existing and novel polymers used in the fabrication of BVMs. Many
of the newer polymers used in the tissue engineering lab have yet to be fully characterized for
biocompatibility. Aim 1 of this thesis involved the development of both direct contact and elutionbased protocols for cytotoxicity testing of polymers. In Aim 2, the protocols were used to assess
the cytotoxicity of existing polymers used in the tissue engineering lab: ePTFE and PLGA. Finally,
in Aim 3, the protocols were used to assess the cytotoxicity of recent polymer additions to the lab:
PLLA, PCL, and PLGA with salt. Overall, the aims of this thesis successfully established methods
that can be used to test and evaluate future scaffold materials used in the fabrication of BVM
models.
5.2 Results and Discussion
5.2.1 Aim 1: Protocol Development
The development of protocols for in vitro cytotoxicity testing of polymers used in BVM
fabrication included numerous trials. Throughout the trials, each iteration brought valuable
contributions. It was shown that a live/dead stain consisting of calcein AM and ethidium
homodimer-1 was a suitable assay for differentiating between live and dead cells in laboratory
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experiments done with human vascular cell types. Additionally, a successful 3T3 cell seeding
density for cytotoxicity testing was determined (i.e., one that did not cause over-confluency and
therefore cell death).
The appropriate positive and negative controls for the direct contact and elution-based
methods were also a significant contribution. As discussed in Section 2.3, the elution controls
displayed inconsistencies and notable cell death with the extraction condition of 50 °C for 72 hours.
The potential generation of precipitates within the cell culture media with a high temperature shift
from 37 °C to 50 °C for a long timepoint may have caused detrimental effects to the cultured cells.
Heat treatment of FBS within the cell culture media has been shown to adversely affect cell health
and lead to these precipitates [72]. The undesirable cell death observed with the extraction condition
of 50 °C for 72 hours led to an incorporation of ISO 10993 cytotoxicity recommendations, and
inevitably brought worthwhile improvements (a new extraction condition of 37 °C for 24 hours and
proper extraction ratios) to the elution-based methods.
Although there were a multitude of trials involved in the development of protocols for in
vitro cytotoxicity testing, the final working protocol included direct contact and elution-based
methods that could suitably evaluate the cytotoxicity of polymers used in BVM fabrication.
5.2.2 Aim 2 and Aim 3: Biocompatibility of Standard and Novel BVM Scaffold Materials
The protocol development trials refined a testing protocol that could properly evaluate the
cytotoxicity of standard and novel BVM scaffold materials used in the tissue engineering lab.
Results gathered from the final biocompatibility evaluation of standard and novel BVM scaffold
materials showed that ePTFE, PLGA, and PLLA were noncytotoxic in elution and direct contact
procedures while PLGA with salt and PCL were noncytotoxic in elution procedures and mildly
cytotoxic in direct contact procedures. These outcomes are outlined in Table 23.
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Table 23. Scaffold material with final cytotoxicity results.
Scaffold Material

Elution Procedure

Direct Contact Procedure

ePTFE

Noncytotoxic

Noncytotoxic

PLGA (solvent: chloroform)

Noncytotoxic

Noncytotoxic

PLGA with salt (solvent: chloroform)

Noncytotoxic

Mildly cytotoxic

PLLA (solvent: chloroform)

Noncytotoxic

Noncytotoxic

PCL (solvent: dichloromethane)

Noncytotoxic

Mildly cytotoxic

The scaffold materials ePTFE, PLGA, and PLLA consistently demonstrated noncytotoxic
effects through elution-based and direct contact methods; therefore, these polymers can be deemed
biocompatible and can be implemented in future lab BVM setups without concerns. Elution-based
cytotoxicity testing of PLGA with salt and PCL illustrated noncytotoxic effects, while direct
contact methods demonstrated mild cytotoxic effects at 24- and 48-hour timepoints (Table 23).
Potential causes for these mild cytotoxic effects are summarized below and were discussed in
further detail in Section 4.3. In summary, the addition of BTEAC salt to PLGA and the use of
dichloromethane as a solvent for PCL could be the cause of cytotoxicity for these samples. Lastly,
due to electrospinner troubleshooting and therefore inadequate sample sizing, an insufficient
extraction ratio associated with the elution procedure could be the cause of differing cytotoxicity
results observed between the two test methods. Future work should be performed to test these
conjectures, which will be further discussed in Section 5.3.
However, if the salt and DCM were definitively problematic, it would have been expected
to see similar cytotoxicity results from the elution procedure. Potential causes for the variability
between test methods include (1) the direct contact procedure’s physical interaction of the test
sample with the cell layer, and (2) the evidence supporting the direct contact procedure’s ability to
better detect cytotoxicity, under the assumption that no physical disruption of the cell layer occurs
during placement of the test sample [83]. As mentioned in Section 4.3, it is important to consider
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the advantages and disadvantages of each test method prior to implementation in cytotoxicity
testing. Each method provides valuable and representative data; therefore, future studies should
continue to implement both direct contact and elution-based methods.
5.3 Limitations and Future Steps
The most notable limitation of this thesis was the troubleshooting of the electrospinner.
Throughout much of the thesis, the electrospinner was unable to produce consistent polymer
scaffolds via mandrel spins (aka “tubular scaffolds). This was limiting because all cytotoxicity
testing was originally intended for electrospun, tube-shaped scaffolds (i.e., standard mandrel spins
used in typical BVM setups). Fortunately, as the year progressed, the electrospinner was able to
produce consistent flat sheet sample spins. Therefore, this limitation was addressed by conducting
cytotoxicity testing on flat sheet sample spins in combination with partial mandrel spins. However,
this led to variability of polymer types and polymer configuration throughout the thesis.
Although the flat sheet samples were usable, they had their disadvantages. The flat sheet
samples were very thin and fibrous which made it challenging to remove them from conicals,
sterilize them in EtOH, and incubate them in media. The thin and fibrous nature of the polymer
spins also made it difficult to obtain the scaffold surface area necessary to reach the desired
extraction ratio in elution procedures. It was sometimes necessary to use multiple tubular scaffold
samples, often more than was accessible, to reach a surface area large enough to properly leach
toxic components from the sample. For example, due to electrospinner troubleshooting, several
scaffold and flat sheet samples were unable to reach the elution procedure’s desired extraction ratio.
To address this limitation, future elution procedures should utilize samples that produce an
approximate extraction ratio of ~45 cm2 in 10 mL of media. This ratio was defined in Trial #8 as
an adequate ratio to properly leach toxins from powder-free latex gloves. Although the
electrospinner limitation was addressed with the methods described above, it is recommended that
future cytotoxicity testing be performed on higher quality and adequately-sized scaffold materials.
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To obtain the elution procedure’s proper extraction ratio of ~45 cm2 in 10 mL of media using a
tubular scaffold, several samples would need to be spun to reach the proper extraction ratio.
Additional limitations associated with protocol development involved improper cell
seeding densities during the first trials. This led to over-confluency of cells in the well plates and
potentially false cytotoxicity conclusions. The positive control for the staining protocol was also a
limitation during the first trials as 100% EtOH for 20 minutes and 70% EtOH for 30-45 seconds
were causing cells to lift from the surface of the wells. Adjustment of the cell seeding protocol and
implementation of methanol for 20 minutes alleviated the over-confluency and positive control
limitations, respectively. Another limitation involved polymer brittleness which resulted in
breakdown in the media during the elution procedure and debris when placing the eluted media on
cells. The polymer brittleness limitation was remedied by using newly spun polymers. Another
limitation involved the application of live/dead stain to cells for 30 minutes which caused the cells
to lift off the surface of the well plates. The stain application troubleshooting was addressed by
ordering new stain and applying a smaller concentration of stain for a shorter timepoint (5-10
minutes). Another notable limitation associated with protocol development involved the
inconsistent outcomes observed with the elution procedure extraction condition of 50 °C for 72
hours. This led to the incorporation of ISO 10993 recommendations which included a new
extraction condition of 37 °C for 24 hours and the introduction of improved extraction ratios. Once
a final testing protocol was established, limitations emerged from the conflicting cytotoxicity
results between the direct contact and elution-based methods.
Future work addressing the conflicting results between the test methods and more
specifically the potential cytotoxic effects of DCM as a solvent for PCL should be conducted. This
could involve dissolving PCL in chloroform—the solvent used for all other polymers—and
evaluating cytotoxic effects thereafter. Chloroform can be a common solvent for PCL applications,
but its use in lab was not pursued due to published protocols that utilized DCM [84],[85].
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Additionally, studies have shown that acetone is a nonhazardous PCL solvent [86]. Other studies
prefer ethyl acetate due to its relatively less toxic nature [87]. Therefore, future work could compare
the feasibility and resulting biocompatibility of various PCL solvent types.
In addition to comparing PCL solvent types, future work could be performed to address
the potential cytotoxic effects from the addition of BTEAC salt to PLGA. This could involve adding
different amounts of BTEAC salt (without the PLGA polymer) directly onto 3T3 cells and
evaluating the cytotoxicity results with a dose response curve. The hypothesis would be that with
little to no salt there would be no cytotoxic response and when the dose of BTEAC salt is increased,
cytotoxicity becomes apparent at a certain threshold. Additionally, various percentages of salt could
be added into the scaffold solutions. For example, 1%, 2%, 5%, and 10% BTEAC salt could be
added into the scaffold solutions and evaluated for a certain threshold where cytotoxic effects begin.
If the BTEAC salt is determined to be cytotoxic at a certain threshold, the next steps would include
determining if the cytotoxicity is permissible for application in the tissue engineering lab or the
potential implementation of a rinsing step to mitigate the cytotoxic effects from the addition of salt
to the scaffold solution.
Another limitation found with cytotoxicity protocols included the lack of quantification for
the direct contact procedure. The lack of quantification made it difficult to distinguish nuances and
make comparisons between each scaffold materials’ cytotoxic effects. Future work to better
quantify the results from the direct contact procedure could include the use of a hemocytometer to
count the number of cells found in the well plate or the further use of ImageJ capabilities. The phase
contrast images taken from the white-light microscope could be evaluated in ImageJ for cell count
or percent surface area covered by cells. Additionally, green fluorescent protein (GFP) 3T3 cells
could be utilized for cytotoxicity testing to better quantify and compare the cytotoxicity of scaffold
materials by means of cell count and cell coverage.
While ISO 10993 recommends established cell lines to be used for cytotoxicity testing, the
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guidance does not recommend a specific cell type [53]. Standard cell types (i.e., mouse fibroblast
cells) are commonly used in literature, but cytotoxicity has been shown to be cell-type dependent
[82]. Therefore, future cytotoxicity testing should be performed using established cell lines other
than 3T3 cells. In the tissue engineering lab, endothelial cells and smooth muscle cells are the
primary cell types that come in direct contact with scaffold materials during BVM setups and
therefore cytotoxicity tests could be performed to evaluate polymer interaction with these cell
types.
Lastly, another iteration of the direct contact procedure with novel materials—PLGA with
salt and PCL—should be conducted to confirm that the mild cytotoxicity observed was due to
biocompatibility concerns of the scaffold materials and not an issue associated with the direct
contact method (i.e., sample placement, physical disturbance of the cell layer). Agar diffusion
techniques could also be implemented as another indirect contact test to provide redundancy and
potentially offer more consistent results [53].
In summary, next steps of this project should include cytotoxicity testing using higher
quality and adequately-sized scaffold materials and another iteration of the direct contact procedure
with novel materials—PLGA with salt and PCL—to confirm observed results. Future work will be
able to utilize the protocols developed in this thesis to prescreen any newly introduced
polymers/materials for their biocompatibility before use in the tissue engineering lab.
5.4 Conclusion
In summary, Aim 1 successfully developed protocols for evaluating scaffold cytotoxicity
with both direct contact and elution-based methods. Aim 2 utilized the protocols to perform
cytotoxicity testing on standard, pre-existing polymers in the tissue engineering lab: ePTFE and
PLGA. Aim 2 studies found that ePTFE and PLGA are noncytotoxic to mouse fibroblast cells.
Therefore, ePTFE and PLGA are safe polymers to be used in scaffold fabrication for BVM models.
Aim 3 utilized the protocols to perform cytotoxicity testing on the tissue engineering lab’s novel
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polymers: PLLA, PCL, and PLGA with salt. Aim 3 studies found that PLLA, PCL, and PLGA with
salt were noncytotoxic to mouse fibroblast cells in elution-based methods; however, the direct
contact procedure illustrated that PLGA with salt and PCL were mildy cytotoxic at 24- and 48-hour
timepoints. The toxicity was mild enough to urge future cytotoxicity testing on PLGA with salt and
PCL before further use in the lab. Meanwhile, ePTFE, PLGA, and PLLA scaffold materials were
deemed biocompatible and can be implemented in future BVM setups.
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Appendix B: Trial #1
Appendix B-1: Trial #1 direct contact procedure with PLGA at the 12-hour timepoint, 10X

Well 1. PLGA

Well 2. PLGA

Well 3. Warmed 3T3 media
from the fridge (neg. control)

Well 4. PLGA

Well 5. PLGA

Well 6. Warmed 3T3 media
from the fridge (neg. control)

Appendix B-2: Trial #1 direct contact procedure with PLGA at the 24-hour timepoint, 10X

Well 1. PLGA

Well 2. PLGA

Well 3. Warmed 3T3 media
from the fridge (neg. control)

Well 4. PLGA

Well 5. PLGA

Well 6. Warmed 3T3 media
from the fridge (neg. control)
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Appendix B-3: Trial #1 direct contact procedure with PLGA at 48-hour timepoint, 10X

Well 1. PLGA

Well 2. PLGA

Well 3. Warmed 3T3 media
from the fridge (neg. control)

Well 4. PLGA

Well 5. PLGA

Well 6. Warmed 3T3 media
from the fridge (neg. control)

Appendix B-4: Trial #1 elution procedure with PLLA at 24-hour timepoint, 10X

Well 1. Warmed 3T3
media from the fridge
(neg. control)

Well 2. Warmed 3T3
media from the fridge
(neg. control)

Well 3. 3T3 media
subjected to 50 °C
water for 72 hours
(neg. control)

Well 5. PLLA eluted
media

Well 4. 3T3 media
subjected to 50 °C
water for 72 hours
(neg. control)

Well 6. PLLA eluted
media
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Well 7. PLLA eluted
media

Appendix C: Trial #2
Appendix C-1: Trial #2 white-light images of ePTFE from direct contact procedure at 12-hour
timepoint, 10X

Well 1. ePTFE scaffold

Well 3. ePTFE scaffold left
in EtOH (pos. control)

Well 5. Warmed 3T3 media
from the fridge (neg. control)

Well 2. ePTFE scaffold

Well 4. ePTFE scaffold left
in EtOH (pos. control)

Well 6. Warmed 3T3 media
from the fridge (neg. control)

Appendix C-2: Trial #2 white-light images of ePTFE from direct contact procedure at 24-hour
timepoint, 10X

Well 1. ePTFE scaffold

Well 3. ePTFE scaffold left in
EtOH (pos. control)

Well 5. Warmed 3T3 media
from the fridge (neg. control)

Well 2. ePTFE scaffold

Well 4. ePTFE scaffold left in
EtOH (pos. control)

Well 6. Warmed 3T3 media
from the fridge (neg. control)
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Appendix C-3: Trial #2 white-light images of ePTFE from direct contact procedure at 48-hour
timepoint, 10X

Well 1. ePTFE scaffold

Well 3. ePTFE scaffold left in
EtOH (pos. control)

Well 5. Warmed 3T3 media
from the fridge (neg. control)

Well 2. ePTFE scaffold

Well 4. ePTFE scaffold left in
EtOH (pos. control)

Well 6. Warmed 3T3 media
from the fridge (neg. control)

Appendix C-4: Trial #2 white-light images of ePTFE from elution procedure at 24-hour
timepoint, 10X

Well 1. Warmed 3T3
media from the fridge
(neg. control)

Well 3. ePTFE
scaffold #2 eluted
media

Well 5. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 2. ePTFE
scaffold #1 eluted
media

Well 4. ePTFE
scaffold #3 eluted
media

Well 6. Warmed 3T3
media from the fridge
(neg. control)
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Micro-dish. Warmed
3T3 media from the
fridge (later used as
pos. control)

Appendix C-5: Trial #2 white-light images of ePTFE from elution procedure at 48-hour
timepoint, 10X

Well 1. Warmed 3T3
media from the fridge
(neg. control)

Well 3. ePTFE
scaffold #2 eluted
media

Well 5. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 2. ePTFE
scaffold #1 eluted
media

Well 4. ePTFE
scaffold #3 eluted
media

Well 6. Warmed 3T3
media from the fridge
(neg. control)
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Micro-dish. Warmed
3T3 media from the
fridge (later used as
pos. control)

Appendix D: Trial #3
Appendix D-1: Trial #3 white light images of ePTFE from elution procedure at 24-hour
timepoint, 10X

Well 1. ePTFE scaffold
soaked in EtOH and flushed
with DPBS eluted media

Well 3. Autoclaved ePTFE
scaffold eluted media

Well 5. ePTFE soaked in
EtOH and thoroughly rinsed
with DPBS eluted media

Well 2. ePTFE scaffold
soaked in EtOH and flushed
with DPBS eluted media

Well 4. Autoclaved ePTFE
scaffold eluted media

Well 6. ePTFE soaked in
EtOH and thoroughly rinsed
with DPBS eluted media

Well 7. 3T3 media in 50 °C
water for 72 hours (neg.
control)

Well 9. Warmed 3T3 media
from the fridge (neg. control)

Micro-dish. Warmed 3T3
media from the fridge (later
used as pos. control)

Well 8. 3T3 media in 50 °C
water for 72 hours (neg.
control)

Well 10. Warmed 3T3 media
from the fridge (neg. control)
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Appendix D-2: Trial #3 white light images of ePTFE from elution procedure at 48-hour
timepoint, 10X

Well 1. ePTFE scaffold
soaked in EtOH and flushed
with DPBS eluted media

Well 3. Autoclaved ePTFE
scaffold eluted media

Well 5. ePTFE soaked in
EtOH and thoroughly rinsed
with DPBS eluted media

Well 2. ePTFE scaffold
soaked in EtOH and flushed
with DPBS eluted media

Well 4. Autoclaved ePTFE
scaffold eluted media

Well 6. ePTFE soaked in
EtOH and thoroughly rinsed
with DPBS eluted media

Well 7. 3T3 media in 50 °C
water for 72 hours (neg.
control)

Well 9. Warmed 3T3 media
from the fridge (neg. control)

Micro-dish. Warmed 3T3
media from the fridge (later
used as pos. control)

Well 8. 3T3 media in 50 °C
water for 72 hours (neg.
control)

Well 10. Warmed 3T3 media
from the fridge (neg. control)
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Appendix E: Trial #4
Appendix E-1: Trial #4 white-light images of 24-hour timepoint elution procedure, 10X

Well 1. PLLA eluted media

Well 3. PLGA eluted media

Well 5. PLGA with salt
eluted media

Well 2. PLLA eluted media

Well 4. PLGA eluted media

Well 6. PLGA with salt
eluted media

Well 7. PCL spun on 210310
eluted media

Well 9. PCL spun on 210215
eluted media

Well 11. PCL scaffold eluted
media

Well 8. PCL spun on 210310
eluted media

Well 10. PCL spun on
210215 eluted media

Well 12. PCL scaffold eluted
media
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Well 13. Warmed
3T3 media from the
fridge (neg. control)

Well 15. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 17. Powder-free
latex glove eluted
media (pos. control)

Well 14. 3T3 media
from the fridge (neg.
control)

Well 16. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 18. Powder-free
latex glove eluted
media (pos. control)

Micro-dish. Warmed
3T3 media from the
fridge (later used as
pos. control)

Appendix E-2: Trial #4 white-light images of 48-hour timepoint elution procedure, 10X

Well 1. PLLA eluted media

Well 3. PLGA eluted media

Well 5. PLGA with salt
eluted media

Well 2. PLLA eluted media

Well 4. PLGA eluted media

Well 6. PLGA with salt
eluted media
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Well 7. PCL spun on 210310
eluted media

Well 9. PCL spun on 210215
eluted media

Well 11. PCL scaffold eluted
media

Well 8. PCL spun on 210310
eluted media

Well 10. PCL spun on
210215 eluted media

Well 12. PCL scaffold eluted
media

Well 13. Warmed
3T3 media from the
fridge (neg. control)

Well 15. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 17. Powder-free
latex glove eluted
media (pos. control)

Well 14. Warmed
3T3 media from the
fridge (neg. control)

Well 16. 3T3 media
warmed to 50 °C for
72 hours (neg.
control)

Well 18. Powder-free
latex glove eluted
media (pos. control)

147

Micro-dish. Warmed
3T3 media from the
fridge (later used as
pos. control)

Appendix F: Trial #5
Appendix F-1: Trial #5 white-light images of 24-hour timepoint elution procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media at 50 °C
for 72 hours (neg. control)

Well 5. Powder-free latex
glove eluted media at 50 °C
for 72 hours (pos. control)

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media at 50 °C
for 72 hours (neg. control)

Well 6. Powder-free latex
glove eluted media at 50 °C
for 72 hours (pos. control)

Appendix F-2: Trial #5 white-light images of 48-hour timepoint elution procedure, 10X

Well 1. . Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media at 50 °C
for 72 hours (neg. control)

Well 5. Powder-free latex
glove eluted media at 50 °C
for 72 hours (pos. control)

Well 2. . Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media at 50 °C
for 72 hours (neg. control)

Well 6. Powder-free latex
glove eluted media at 50 °C
for 72 hours (pos. control)
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Appendix G: Trial #6
Appendix G-1: Trial #6 white-light images of 24-hour timepoint elution procedure, 10X
50 °C for 24 hours:

Well 1. 3T3 media warmed to
50 °C for 24 hours

Well 3. 5.4 cm2 powder-free
latex glove eluted media

Well 5. 60 cm2 powder-free
latex glove eluted media

Well 2. 3T3 media warmed to
50 °C for 24 hours

Well 4. 5.4 cm2 powder-free
latex glove eluted media

Well 6. 60 cm2 powder-free
latex glove eluted media

Well 13. 3T3 media warmed
to 50 °C for 72 hours

Well 15. 5.4 cm2 powder-free
latex glove eluted media

Well 17. 60 cm2 powder-free
latex glove eluted media

Well 14. 3T3 media warmed
to 50 °C for 72 hours

Well 16. 5.4 cm2 powder-free
latex glove eluted media

Well 18. 60 cm2 powder-free
latex glove eluted media

50 °C for 72 hours:
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37 °C for 24 hours:

Well 19. 3T3 media warmed
to 37 °C for 24 hours

Well 21. 5.4 cm2 powderfree latex glove eluted media

Well 23. 60 cm2 powder-free
latex glove eluted media

Well 20. 3T3 media warmed
to 37 °C for 24 hours

Well 22. 5.4 cm2 powderfree latex glove eluted media

Well 24. 60 cm2 powder-free
latex glove eluted media

Well 7. 3T3 media warmed
to 37 °C for 72 hours

Well 9. 5.4 cm2 powder-free
latex glove eluted media

Well 11. 60 cm2 powder-free
latex glove eluted media

Well 8. 3T3 media warmed
to 37 °C for 72 hours

Well 10. 5.4cm^2 powderfree latex glove

Well 12. 60 cm2 powder-free
latex glove eluted media

37 °C for 72 hours:
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Micro-dishes:

Well 25. Warmed 3T3 media from the fridge

Well 26. Warmed 3T3 media from the fridge

Appendix G-2: Trial #6 white-light images of 48-hour timepoint elution procedure, 10X
50 °C for 24 hours:

Well 1. 3T3 media warmed to
50 °C for 24 hours

Well 3. 5.4 cm2 powder-free
latex glove eluted media

Well 5. 60 cm2 powder-free
latex glove eluted media

Well 2. 3T3 media warmed to
50 °C for 24 hours

Well 4. 5.4 cm2 powder-free
latex glove eluted media

Well 6. 60 cm2 powder-free
latex glove eluted media
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50 °C for 72 hours:

Well 7. 3T3 media warmed
to 50 °C for 72 hours

Well 9. 5.4 cm2 powder-free
latex glove eluted media

Well 11. 60 cm2 powder-free
latex glove eluted media

Well 8. 3T3 media warmed
to 50 °C for 72 hours

Well 10. 5.4 cm2 powderfree latex glove eluted media

Well 12. 60 cm2 powder-free
latex glove eluted media

Well 13. 3T3 media warmed
to 37 °C for 24 hours

Well 15. 5.4 cm2 powderfree latex glove eluted media

Well 17. 60 cm2 powder-free
latex glove eluted media

Well 14. 3T3 media warmed
to 37 °C for 24 hours

Well 16. 5.4 cm2 powderfree latex glove eluted media

Well 18. 60 cm2 powder-free
latex glove eluted media

37 °C for 24 hours:
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37 °C for 72 hours:

Well 19. 3T3 media warmed
to 37 °C for 72 hours

Well 21. 5.4 cm2 powderfree latex glove eluted media

Well 23. 60 cm2 powder-free
latex glove eluted media

Well 20. 3T3 media warmed
to 37 °C for 72 hours

Well 22. 5.4 cm2 powderfree latex glove eluted media

Well 24. 60 cm2 powder-free
latex glove eluted media

Micro-dishes:

Well 25. Warmed 3T3 media from the fridge

Well 26. Warmed 3T3 media from the fridge
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Appendix H: Trial #8
Appendix H-1: Trial #8 white-light images of 24-hour timepoint elution procedure, 10X

Well 1. 3T3 media warmed to
37 °C for 24 hours

Well 3. 6 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 5. 15 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 2. 3T3 media warmed to
37 °C for 24 hours

Well 4. 6 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 6. 15 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 7. 30 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 9. 45 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 11. 60 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 8. 30 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 10. 45 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 12. 60 cm2 latex eluted
media warmed to 37°C for 24
hours
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Micro-dish. Warmed 3T3 media from the
fridge

Micro-dish. Warmed 3T3 media from the
fridge

Appendix H-2: Trial #8 white-light images of 48-hour timepoint elution procedure, 10X

Well 1. 3T3 media warmed to
37 °C for 24 hours

Well 3. 6 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 5. 15 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 2. 3T3 media warmed to
37 °C for 24 hours

Well 4. 6 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 6. 15 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 7. 30 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 9. 45 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 11. 60 cm2 latex eluted
media warmed to 37°C for 24
hours
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Well 8. 30 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 10. 45 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 13. Warmed 3T3 media from the fridge
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Well 12. 60 cm2 latex eluted
media warmed to 37°C for 24
hours

Well 14. Warmed 3T3 media from the fridge

Appendix I: Aim 3: Cytotoxicity Testing of ePTFE and PLGA

Appendix I-1: White-light images of 12-hour timepoint direct contact procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 3. PLGA

Well 5. PLGA in EtOH (pos.
control)

Well 4. ePTFE

Well 6. ePTFE in EtOH (pos.
control)

Appendix I-2: White-light images of 24-hour timepoint direct contact procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. PLGA

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. ePTFE
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Well 5. PLGA in EtOH (pos.
control)

Well 6. ePTFE in EtOH
(pos. control)

Appendix I-3: White-light images of 48-hour timepoint direct contact procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 3. PLGA

Well 4. ePTFE

Well 4. PLGA in EtOH (pos.
control)

Well 6. ePTFE in EtOH
(pos. control)

Appendix I-4: White-light images of 24-hour timepoint elution procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media warmed to
37 °C for 24 hours

Well 5. 45 cm2 latex eluted
media warmed to 37 °C for
24 hours

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media warmed to
37 °C for 24 hours

Well 6. 45 cm2 latex eluted
media warmed to 37 °C for
24 hours
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Well 7. PLGA scaffold eluted
media

Well 9. PLGA flat sheet
eluted media

Well 11. ePTFE scaffold
eluted media

Well 8. PLGA scaffold eluted
media

Well 10. PLGA flat sheet
eluted media

Well 12. ePTFE scaffold
eluted media

Appendix I-5: White-light images of 48-hour timepoint elution procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media warmed to
37 °C for 24 hours

Well 5. 45 cm2 latex eluted
media warmed to 37 °C for
24 hours

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media warmed to
37 °C for 24 hours

Well 6. 45 cm2 latex eluted
media warmed to 37 °C for
24 hours
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Well 7. PLGA scaffold eluted
media

Well 9. PLGA flat sheet
eluted media

Well 11. ePTFE scaffold
eluted media

Well 8. PLGA scaffold eluted
media

Well 10. PLGA flat sheet
eluted media

Well 12. ePTFE scaffold
eluted media
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Appendix J: Aim 3: Cytotoxicity Testing of PLLA, PLGA with salt, and PCL

Appendix J-1: White-light images of 12-hour timepoint direct contact procedure, 10X

Well 1. PLLA

Well 2. PLLA

Well 3. PLLA in EtOH (pos.
control)

Well 5. PLGA with salt

Well 4. PLGA with salt in
EtOH (pos. control)

Well 6. PLGA with salt

Well 7. PCL flat sheet
210310

Well 9. PCL in EtOH (pos.
control)

Well 11. PCL flat sheet
210215

Well 8. PCL flat sheet
210310

Well 10. PCL flat sheet
210215

Well 12. PCL scaffold
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Well 13. PCL scaffold

Well 14. Warmed 3T3 media
from the fridge (neg. control)

Well 15. Warmed 3T3 media
from the fridge (neg. control)

Appendix J-2: White-light images of 24-hour timepoint direct contact procedure, 10X

Well 1. PLLA

Well 3. PLLA in EtOH (pos.
control)

Well 5. PLGA with salt

Well 2. PLLA

Well 4. PLGA with salt in
EtOH (pos. control)

Well 6. PLGA with salt

Well 7. PCL flat sheet
210310

Well 9. PCL in EtOH (pos.
control)
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Well 11. PCL flat sheet
210215

Well 8. PCL flat sheet
210310

Well 13. PCL scaffold

Well 10. PCL flat sheet
210215

Well 14. Warmed 3T3 media
from the fridge (neg. control)

Well 12. PCL scaffold

Well 15. Warmed 3T3 media
from the fridge (neg. control)

Appendix J-3: White-light images of 48-hour timepoint direct contact procedure, 10X

Well 1. PLLA

Well 3. PLLA in EtOH (pos.
control)

Well 5. PLGA with salt

Well 2. PLLA

Well 4. PLGA with salt in
EtOH (pos. control)

Well 6. PLGA with salt
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Well 7. PCL flat sheet
210310

Well 8. PCL flat sheet
210310

Well 13. PCL scaffold

Well 9. PCL in EtOH (pos.
control)

Well 11. PCL flat sheet
210215

Well 10. PCL flat sheet
210215

Well 12. PCL scaffold

Well 14. Warmed 3T3 media
from the fridge (neg. control)
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Well 15. Warmed 3T3 media
from the fridge (neg. control)

Appendix J-4: White-light images of 24-hour timepoint elution procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media warmed to
37 °C for 24 hours (neg.
control)

Well 5. Powder-free latex
glove eluted media (pos.
control)

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media warmed to
37 °C for 24 hours (neg.
control)

Well 6. Powder-free latex
glove eluted media (pos.
control)

Well 7. PLGA w/ salt
scaffold eluted media

Well 9. PLGA w/ salt flat
sheet eluted media

Well 11. PLLA scaffold
eluted media

Well 8. PLGA w/ salt
scaffold eluted media

Well 10. PLGA w/ salt flat
sheet eluted media

Well 12. PLLA scaffold
eluted media
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Well 13. PLLA flat sheet
eluted media

Well 15. PCL scaffold eluted
media

Well 17. PCL flat sheet
eluted media

Well 14. PLLA flat sheet
eluted media

Well 16. PCL scaffold eluted
media

Well 18. PCL flat sheet
eluted media

Micro-dish. Warmed 3T3
media from the fridge (later
used as a pos. control)

Appendix J-5: White-light images of 48-hour timepoint elution procedure, 10X

Well 1. Warmed 3T3 media
from the fridge (neg. control)

Well 3. 3T3 media warmed to
37 °C for 24 hours (neg.
control)
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Well 5. Powder-free latex
glove eluted media (pos.
control)

Well 2. Warmed 3T3 media
from the fridge (neg. control)

Well 4. 3T3 media warmed to
37 °C for 24 hours (neg.
control)

Well 6. Powder-free latex
glove eluted media (pos.
control)

Well 7. PLGA w/ salt
scaffold eluted media

Well 9. PLGA w/ salt flat
sheet eluted media

Well 11. PLLA scaffold
eluted media

Well 8. PLGA w/ salt
scaffold eluted media

Well 10. PLGA w/ salt flat
sheet eluted media

Well 12. PLLA scaffold
eluted media

Well 13. PLLA flat sheet
eluted media

Well 15. PCL scaffold eluted
media

Well 17. PCL flat sheet
eluted media
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Well 14. PLLA flat sheet
eluted media

Well 16. PCL scaffold eluted
media

Micro-dish. Warmed 3T3
media from the fridge (later
used as a pos. control)
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Well 18. PCL flat sheet
eluted media

Appendix K: Cytotoxicity Testing: Cell Seeding SOP
Approx. Time:

1 hour

Abbreviations:

1. EtOH – ethanol

Reminders:

1. Be sure to
manually aspirate
whenever the
protocol says
“Aspirate”
2. Always spray
items with 70%
EtOH before placing
them in hood
3. Spray hands with
70% EtOH often,
particularly after
taking them out of
the hood
4. Be organized in
the hood

Materials:

Micro-dish

Procedure:
A. Preparation
1. Always wash hands thoroughly before beginning.
2. Assure lab safety by wearing gloves, shoes, and pants.
3. Place 3T3 media and 3T3 trypsin into a water bath to warm up.
4. “Open” the hood by raising the door to the marked line, turning
on the light and pump, and thoroughly spraying with 70%
EtOH.
5. Wipe microscope stage with 70% EtOH.
6. Check confluency of 3T3 cells.
6.1. Should be 80-100% confluent before seeding.
7. Acquire the necessary number of packaged sterile 6-well
plate(s) and bring into hood.
7.1 If performing elution, bring sterile, glass bottom
micro-dish into hood as well. *Ethanol treatment
should not be used in the 6-well plate to prevent crosscontamination of EtOH into negative control and
polymer samples*
7.2 If performing elution, use double the number of 6well plate(s) for 24- and 48-hour timepoints.
B. Seeding
8. Using previously warmed 3T3 media, place 2 mL of media into
each well of the 6-well plate(s) and micro-dish.
1.1 Let these incubate while performing next steps.
9. *Follow steps B.1 - B.6 from SOP 3021 for passing 3T3 cells*
10. Pipette out all cell solution and place in a 50 mL conical.
3.1 Spin down cells into a pellet using centrifuge at
setting 4 for 4 minutes.
3.2 Bring spun down cells into hood and aspirate out
media, leaving cell pellet at the bottom.
3.3 Resuspend in 24 mL of 3T3 media.
3.4 Agitate the solution to ensure that all cells are
evenly distributed.
11. Label the dishes with cell type (3T3), initials, date, and other
relevant information.
12. Pipette 0.3 mL of the cell solution to each well of 6-well plates
and micro-dish.
13. Carefully place the lids onto the 6-well plate(s) and micro-dish
with aseptic technique and transfer to the incubator.
14. Allow cells to incubate overnight before performing direct
contact and/or elution procedure.

6-well plate(s)
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Appendix L: Cytotoxicity Testing: Direct Contact SOP
Approx. Time:

Procedure:

1 hour

A. Preparation
1. Remove the 6-well plate(s) from the incubator.
2. Check and record cell confluency of each well under white-light
microscope.
2.1. Well plate should be 60-70% confluent before
procedure.
3. Take a Phase Contrast image of cell confluency under the white-light
microscope.
4. Place the well plate(s) back into the incubator until needed for direct
contact.

Abbreviations:

1. EtOH – ethanol
2. DPBS – Dulbecco’s
phosphate buffered
saline

Reminders:

1. Be sure to manually
aspirate whenever the
protocol says
“Aspirate”
2. Always spray items
with 70% EtOH
before placing them in
hood
3. Spray hands with
70% EtOH often,
particularly after
taking them out of the
hood
4. Be organized in the
hood

Materials:
Scaffold samples
6 well plate(s)
Sterile forceps
Nonsterile forceps
Sterile 70% EtOH
DPBS

B. Direct Contact
1. Bring sterile and nonsterile forceps into the hood.
2. Bring (~ 6 cm2 surface area) samples into hood on a labeled paper
towel.
3. Place 12mL of 70% sterile EtOH into the proper amount of conicals.
3.1 One conical per sample.
3.2 Invert conicals.
4. Use the nonsterile forceps to grab each sample and place into
the corresponding conical of 70% sterile EtOH.
4.1 Label the conicals with the sample type.
4.2 Let these samples sit in EtOH for 20 minutes.
4.3 Invert all conicals at beginning and end of 20 minutes.
5. While waiting, replace the 2 mL of 3T3 media in 6-well plate(s).
6. After 20 minutes of sterilization, aspirate out the EtOH and replace
with sterile DPBS.
6.1 Leave one of each sample subjected to EtOH (don’t rinse
with DPBS) for use as positive control.
6.2 Thoroughly rinse the samples in DPBS for 1 minute by
vigorously shaking the conical.
7. Bring the well plate(s) into the hood and uncover.
8. Use long sterile forceps to grab each sample out of DPBS.
9. Place the previously sterilized and rinsed samples into corresponding
wells.
10. Cover the well plate(s) and label each well with sample type.
11. Place the well plate(s) back into the incubator.
C. White-Light Imaging
1. At 12-, 24-, and 48-hours after placing the scaffold samples into the
well plate(s), take Phase Contrast images of each well under the
white-light microscope.
1.1 Take three images per well (take note of where the
image is in relation to the sample).
1.2 Save images and place into corresponding folder.
1.3 After 48 hours, remove the samples from the well
plate and image underneath the sample.
2. Dispose of the well plate(s).
3.1 Place samples into biohazard if still solid and
aspirate out the cells and media before discarding into
biohazard.
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Appendix M: Cytotoxicity Testing: Elution SOP
Approx. Time:
1 hour

Abbreviations:

1. EtOH – ethanol
2. DPBS – Dulbecco’s
phosphate buffered
saline

Reminders:

1. Be sure to manually
aspirate whenever the
protocol says
“Aspirate”
2. Always spray items
with 70% EtOH
before placing them in
hood
3. Spray hands with
70% EtOH often,
particularly after
taking them out of the
hood
4. Be organized in the
hood

Materials:

Procedure:
A. Preparation
1. Bring nonsterile forceps, along with (~45 cm2 surface area) samples
into hood on a labeled paper towel.
2. Bring appropriate amount of conicals into hood and label with
polymer type.
2.1 One conical per sample.
3. Place 12 mL of 70% sterile EtOH into each conical.
3.1 Invert conical.
4. Use the nonsterile forceps to grab each sample and place into the
corresponding conical of 70% sterile EtOH.
4.1 If sample doesn’t easily fit into conical, cut into strips.
4.2 Let these samples sit in the EtOH for 20 minutes.
4.3 Invert all conicals at beginning and end of 20 minutes.
5. While waiting, prepare separate 15 mL conicals with 10 mL of 3T3
media and label with corresponding treatment and sample type.
5.1 One conical per sample, plus one conical for the
incubated media control, plus one for latex glove control.
6. After 20 minutes of sterilization, aspirate out the EtOH and replace with
DPBS.
6.1 Thoroughly rinse the samples in 10 mL DPBS for 1
minute by thoroughly shaking the conical.
7. Aspirate out DPBS and with long sterile forceps transfer the scaffolds
from their conicals to corresponding conicals prepared with media.
8. Include 10mL of just media (no sample) as negative control.
9. Include a 45cm^2 sample of sterile, powder-free latex glove in 10 mL
of media as positive control.
9.1 Use sterile scissors and sterile gloves to cut piece and
place into media.
10. Place all labeled conicals in incubator at 37 °C for 24 hours.
11. 24 hours later... remove the scaffolds with sterile forceps.
11.1 Take pictures of scaffolds before discarding.
12. Place the eluted media into the fridge.
B. Preparation for Placement onto Cells
1. Remove the previously seeded well plate(s) and micro-dish from the
incubator.
2. Check and record cell confluency of each well under white-light
microscope.
2.1. Wells should be 60-70% confluent before procedure.
3. Take a Phase Contrast image of cell confluency under the white-light
microscope.
C. Cell Culture
1. Aspirate out old media from the 6-well plate(s) and micro-dish.

6-well plate(s)
Micro-dish

2. Place 1.5mL of eluted media into corresponding wells of 6-well
plate(s) and label accordingly for 24- and 48-hour timepoints.

Sterile 70% EtOH

3. Replace 3T3 media in micro-dish.

Sterile forceps

3. Place well plate(s) and micro-dish back into incubator until staining

Nonsterile forceps

and imaging.
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Appendix N: Staining SOP – Calcein AM & Ethidium Homodimer-1
Approx. Time:

Procedure:

1 hour

A. Preparation
1. Remove the well plate(s) and micro-dish from the incubator.
2. Check and record cell confluency of each well under white-light
microscope.
3. Take 3 Phase Contrast images of each well under the white-light
microscope and take note of qualitative observations.
4. Place the well plate(s) and micro-dish back into the incubator until
the stain solution is prepared.

Abbreviations:
1. EtOH – ethanol
2. DPBS – Dulbecco’s
phosphate buffered
saline
3. EthD-1 – ethidium
homodimer-1

Reminders:

1. Tilt the 6-well plate
at an angle, using the
pipette tip to
“aspirate” into waste
conical.
2. Place any solution
at edge of well, careful
not to blast the cells.
3. Always spray items
with 70% EtOH before
placing them in hood
4. Spray hands with
70% EtOH often,
particularly after
taking them out of the
hood
Materials:
Live/Dead stain
6-well plate(s)

B. Calcein AM & Ethidium Homodimer-1 Stain
5. Remove Calcein AM & Ethidium Homodimer-1 from the freezer.
5.1 Wrap in tinfoil to protect from light. Let thaw
completely.
6. Grab Methanol from flammables cabinet.
7. Aspirate media from micro-dish.
8. Pipette 2mL of Methanol into micro-dish and allow to sit for 20
minutes.
9. While this is sitting, make the Live/Dead assay stock solution in a
50mL conical.
11.1 Spray down sterile pipette tips and micropipette and
bring
into hood.
11.2 Stock Solution: 10 mL DPBS + 12 uL EthD-1 + 3
uL Calcein AM. * May need to adjust this
depending on how many wells there are.
10. Cover the stock solution in tinfoil to protect from light and bring 6well plate(s) and micro-dish from incubator to center of hood.
11. After 20 minutes, aspirate Methanol from micro-dish and rinse with
DPBS.
12. Carefully aspirate media out of all other wells.
13. Rinse each well with DPBS.
14. Carefully aspirate out DPBS from each well. Cover the 6-well
plate(s) and micro-dish.
15. Uncap Live/Dead stock stain solution with aseptic technique.
16. Pipette 1.5mL of stock stain solution into each well and micro-dish.
16.1 Cover in tinfoil to protect from light.
17. Allow stain to sit on cells for 5-10 minutes.
18.1 Immediately bring well plates to 330 for imaging.
18. After 5-10 minutes, aspirate out stain.
19. Image cells right away.
21.1 Take 3 images per well.
21.2 On the microscope, unscrew all magnifications other
than 4 and 10X.
21.3 Turret 2 for Calcein AM and turret 6 for EthD-1.

Micro-dish
DPBS
Methanol
70% EtOH
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Appendix O: Imaging with Widefield Fluorescence Microscope SOP
Approx. Time:

1 Hour

Reminders:
1. Live/Dead is light
sensitive. Always
keep wrapped in foil
and limit exposure to
light.
2. Obtain permission
from Dr. Cardinal
and/or Dr. Lily Laiho
before using the
fluorescent
microscope.
3. This is a VERY
expensive piece of
equipment— always
use care during
operation.
4. Lamp should be
turned on 10-15 mins
prior to taking images.

Procedure:
A. Microscope Operation
1. Log into notebook—fluorescence, initials, date, time, and lamp hours.
2. Turn microscope on using fluorescent settings.
a. Turn turret to setting 2.
b. Power on Olympus lamp (black switch on top of microscope).
c. Turn on Olympus lamp (push “on/off” button and turn dial up).
d. Turn on Optiscan wheels (green switch).
e. Set filter wheel 1 to 10, and set filter wheel 2 to 10.
f. Open shutter (by sliding to icon of open circle).
g. Set Prior keypad to shutter S1.
h. Dial objectives to desired magnification (typically 10x).
i. Set thin bar to icon of camera (pull all the way out).
3. Sign into computer by clicking Kristen’s account (password can be
obtained from Kristen).
4. Place samples on microscope stage.
5. Manually adjust microscope to clarify image.
B. Capturing Images
1. Click QCapture Pro (on desktop).
2. Click camera icon at upper left corner of QCapture Pro window and
preview.
3. “Snap “pictures”. Save pictures if desired (labeled with sample
info, initials, and magnification).
4. Save files on a flash drive.
4.1. Quit QCapture Pro. Log out of computer.
4.2. Log out of notebook. Shut down microscope by
switching off Olympus lamp, switching off Optiscan wheels,
switching off camera (on top of microscope), closing shutter and
setting thin bar to icon of eye.

5. If sample is too wet,
carefully blot edge of
sample with a Kim
wipe.
6. Promptly report all
microscope issues to
Dr. Laiho.

Materials:
Samples
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Appendix P: Cell Counting with ImageJ SOP
Approx. Time:

1 hour

Abbreviations:

Reminders:

1. Optimize the
threshold or else
counts will be skewed.

Procedure:
A. Counting Cell Nuclei
1. Open the image in ImageJ.
2. Plugins à Macros à Record...
3. Image à Type à 16-bit
4. Edit – Options – Conversions to “scale when converting”
5. Image à Adjust à Threshold
5.1 Mess around with the threshold until looks clearer.
6. Adjust your threshold so that the nuclei will be counted individually.
Hit “apply” when satisfied.
6.1 Optimize this or else all counts will be skewed.
7. Process à Binary à Watershed
8. Analyze à Analyze Particles (50-Infinity) in pixel^2 units
9. Change “show”’ to Bare Outlines
10. Make sure “summarize” and “display results” are checked.
11. In the summary pop up, the count will be the number of nuclei.
12. Cross reference the nuclei in the original image against the counted
image to make sure non-nuclei are not being counted.
13. Hit “Create” on the Macro recorder.
The macro should read...
run("16-bit");
run("Conversions...", "scale");

Materials:
ImageJ software

setAutoThreshold("Default dark");
//run("Threshold...");
setOption("BlackBackground", true);
run("Convert to Mask");
run("Watershed");
run("Analyze Particles...", "size=50-Infinity show=[Bare Outlines]
display summarize");
14. Use this Macro for all following images.
15. Open the image in ImageJ.
16. Control + R will perform the recorded Macro on each following
image.
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